<SEC-DOCUMENT>0001193125-25-275659.txt : 20251112
<SEC-HEADER>0001193125-25-275659.hdr.sgml : 20251112
<ACCEPTANCE-DATETIME>20251112060805
ACCESSION NUMBER:		0001193125-25-275659
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20251112
DATE AS OF CHANGE:		20251112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811591163
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-285969
		FILM NUMBER:		251468289

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		SUITE 1350
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		SUITE 1350
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d89411d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR>Registration No. 333-285969 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Prospectus supplement</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To prospectus dated March&nbsp;31, 2025) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>10,000,000 Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g89411g51v03.jpg" ALT="LOGO" STYLE="width:1.65906in;height:0.566153in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering 10,000,000 shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#8220;VOR.&#8221; On November&nbsp;10, 2025, the last reported
sale price of our common stock on The Nasdaq Global Select Market was $18.80&nbsp;per share. All share and per share numbers presented herein give effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-20</FONT></FONT>
reverse stock split of our common stock effected on September&nbsp;18, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; and a
&#8220;smaller reporting company&#8221; as defined under applicable Securities and Exchange Commission rules and are subject to reduced public company reporting requirements. See &#8220;Prospectus Supplement Summary&#8212;Implications of Being an
Emerging Growth Company and a Smaller Reporting Company.&#8221; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Vor Biopharma Inc. (before expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See &#8220;Underwriting&#8221; for additional disclosure regarding underwriting compensation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase up to an additional 1,500,000 shares of our common stock at the
public offering price, less underwriting discounts and commissions, within 30&nbsp;days from the date of the final prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See &#8220;<A HREF="#supptoc89411_3">Risk Factors</A>&#8221; on <FONT
STYLE="white-space:nowrap">page&nbsp;S-9</FONT> of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares to purchasers on or about November 12, 2025. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><B>J.P.&nbsp;Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>TD&nbsp;Cowen</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November 10, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_4">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_7">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_8">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_11">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc89411_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus relate to an offering of our common stock. Before buying any of the common stock
that we are offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference as described under the headings &#8220;Where You Can Find More Information&#8221;
and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus supplement. These documents contain important information that you should consider when making your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified or required by context, references in this prospectus supplement to &#8220;Company,&#8221; &#8220;Vor
Biopharma,&#8221; &#8220;Vor Bio,&#8221; &#8220;Vor,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Vor Biopharma Inc. and its consolidated subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering of common stock and
also adds to, updates and changes information contained in the accompanying prospectus and the documents incorporated by reference. The second part is the accompanying prospectus, which gives more general information. To the extent the information
contained in this prospectus supplement differs from or conflicts with the information contained in the accompanying prospectus or any document incorporated by reference, the information in this prospectus supplement will control. If any statement
in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference into the accompanying prospectus&#8212;the statement in the document having the later date
modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not, and the underwriters have not, authorized anyone to provide you with
information different from that which is contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we have authorized for use in connection with this offering. No one
is making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus supplement is accurate as of the date on the front
cover of this prospectus supplement only and that any information we have incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the document incorporated by reference or as of the date of the
prospectus, as applicable, regardless of the time of delivery of this prospectus supplement, the accompanying prospectus, any related free writing prospectus, or any sale of our common stock. Our business, financial condition, results of operations
and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any
agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for
the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made.
Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;VOR&#8221;, &#8220;VOR BIO&#8221;, &#8220;VOR BIOPHARMA&#8221; and the Vor logo and other trademarks, trade names or service marks of
Vor Biopharma Inc. appearing in this prospectus are the property of Vor Biopharma Inc. This prospectus supplement, the accompanying prospectus and the information incorporated herein and therein by reference may include trademarks, service marks and
trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus supplement or the accompanying prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and the
accompanying prospectus. This summary does not contain all the information you should consider before investing in our common stock. You should read and consider carefully the more detailed information in this prospectus supplement and the
accompanying prospectus, including the factors described under the heading &#8220;Risk Factors&#8221; in this prospectus supplement and the financial and other information incorporated by reference in this prospectus supplement and the accompanying
prospectus, as well as the information included in any free writing prospectus that we have authorized for use in connection with this offering, before making an investment decision. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on developing a novel therapy for the treatment of autoimmune diseases. In June 2025, <FONT STYLE="white-space:nowrap">we&nbsp;in-licensed&nbsp;telitacicept</FONT> from RemeGen Co., Ltd. (&#8220;RemeGen&#8221;).
Telitacicept is approved in China for the treatment of systemic lupus erythematosus (&#8220;SLE&#8221;), rheumatoid arthritis (&#8220;RA&#8221;) and generalized myasthenia gravis (&#8220;gMG&#8221;). A global Phase 3 clinical trial in gMG is
currently underway across the United States, Europe, South America and Asia, including Japan, to support potential approval in such jurisdictions. Telitacicept is a novel fusion protein for treating autoimmune diseases. It is constructed with the
extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor receptor and the fragment crystallizable domain of human immunoglobulin G. Telitacicept targets and acts on two cell signaling
molecules critical for B lymphocyte development: B cell lymphocyte stimulator, also known as B cell activating factor (&#8220;BAFF&#8221;) and a proliferation inducing ligand (&#8220;APRIL&#8221;), which allows it to effectively reduce B cell
mediated autoimmune responses that are implicated in several autoimmune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our license agreement with RemeGen, we were
granted an exclusive license to develop and commercialize telitacicept outside of the Greater China region, which includes mainland China, Hong Kong, Macau and Taiwan. RemeGen retains development and commercialization rights in Greater China. Our
broader development plan includes exploring development of telitacicept in additional autoantibody-driven diseases where BAFF / APRIL signaling is a validated target, supported by prior clinical experience and mechanistic rationale. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Generalized Myasthenia Gravis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telitacicept is approved in China for the treatment of systemic lupus erythematosus, rheumatoid arthritis and gMG. gMG is a rare, chronic
autoimmune neuromuscular disorder characterized by fluctuating skeletal muscle weakness resulting from pathogenic autoantibodies, most frequently the targeting components of the neuromuscular junction. These autoantibodies, about 85% of which are
acetylcholine receptor and <FONT STYLE="white-space:nowrap">5-8%</FONT> of which are muscle-specific tyrosine kinase, impair synaptic transmission, leading to a disabling and potentially life-threatening condition that requires long-term
immunomodulation to control disease activity. gMG has a prevalence of approximately 150 to 250 individuals per million worldwide, with a rising incidence among aging populations. In the United States, based on a 2021 claims analysis, the prevalence
is thought to be comparable to Europe at approximately 370 individuals per million, and it is estimated that approximately 100,000 individuals have MG in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telitacicept was evaluated by RemeGen in a Phase 3 clinical trial in patients with gMG in China. In April 2025, RemeGen presented <FONT
STYLE="white-space:nowrap">24-week</FONT> data from its Phase 3 clinical trial in gMG in China which demonstrated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Myasthenia Gravis Activities of Daily Living <FONT STYLE="white-space:nowrap">(&#8220;MG-ADL&#8221;)</FONT>
score decreased by 5.74 points (4.8 points placebo adjusted) from baseline in the telitacicept group, compared to a decrease of 0.91 points in the placebo group (note: missing data imputed as <FONT STYLE="white-space:nowrap">non-response).</FONT>
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Quantitative Myasthenia Gravis (&#8220;QMG&#8221;) score decreased by 8.66 points (6.4 points placebo
adjusted) from baseline in the telitacicept group, compared to a decrease of 2.27 points in the placebo group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">98.1% of patients in the telitacicept group demonstrated a &#8805;
<FONT STYLE="white-space:nowrap">3-point</FONT> improvement in <FONT STYLE="white-space:nowrap">MG-ADL</FONT> score, compared to 12.0% in the placebo group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">87.0% of patients in the telitacicept group demonstrated a &#8805;
<FONT STYLE="white-space:nowrap">5-point</FONT> improvement in QMG score, compared to 16.0% in the placebo group. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telitacicept demonstrated significant clinical improvement in disease activity with a favorable safety profile.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consistent reduction in IgG, IgA, IgM and B cells. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The overall adverse event rate in the telitacicept group was comparable to that in the placebo group, indicating
telitacicept was well-tolerated. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data from the <FONT STYLE="white-space:nowrap">open-label</FONT> treatment period
(Part&nbsp;B) of the Phase&nbsp;3 trial were presented by RemeGen at the American Association of Neuromuscular&nbsp;&amp; Electrodiagnostic Medicine (&#8220;AANEM&#8221;) meeting in October 2025. The data at week 48 demonstrated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients on telitacicept throughout the trial achieved a <FONT STYLE="white-space:nowrap">-7.5</FONT> mean <FONT
STYLE="white-space:nowrap">MG-ADL</FONT> change from baseline, while placebo crossover patients achieved <FONT STYLE="white-space:nowrap">-6.3;</FONT> 96.2% of continuous patients and 90.2% of crossover patients reached <FONT
STYLE="white-space:nowrap">&#8805;3-point</FONT> improvement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients on telitacicept throughout the trial achieved a <FONT STYLE="white-space:nowrap">-9.8</FONT> mean QMG
change from baseline, while placebo crossover patients achieved <FONT STYLE="white-space:nowrap">-9.3;</FONT> 94.2% of continuous patients and 90.2% of crossover patients reached <FONT STYLE="white-space:nowrap">&#8805;5-point</FONT> improvement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telitacicept demonstrated a favorable safety profile comparable to placebo and consistent with prior clinical
trials and <FONT STYLE="white-space:nowrap">post-marketing</FONT> data across other autoimmune indications, including SLE, RA, pSD and IgA nephropathy. No new safety signals were observed. Most adverse events were mild to moderate in severity.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No injection site reactions were reported during the <FONT STYLE="white-space:nowrap">open-label</FONT> extension
period in patients previously on telitacicept. Injection site reactions in placebo crossover patients were mild, <FONT STYLE="white-space:nowrap">self-resolving</FONT> and did not lead to discontinuation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telitacicept is currently being evaluated in a global Phase 3 clinical trial, for which we are assuming responsibility from RemeGen in
connection with the license agreement, for the treatment of gMG. The trial is currently recruiting patients in North America, Europe, Latin America, and Asia to support potential approval in the United States, Europe, and Japan and other countries.
The trial is a randomized, double-blind, placebo controlled trial with an open-label extension period. The primary endpoint is change from baseline in <FONT STYLE="white-space:nowrap">MG-ADL</FONT> at week 24. Key secondary endpoints include change
from baseline in QMG score, proportion of patients achieving <FONT STYLE="white-space:nowrap">MG-ADL</FONT> score reduction of at least 2 points, proportion of patients achieving QMG score reduction of at least 3 points at week 24 and change from
baseline in MG Quality of Life scale at week 24. In July 2024, the clinical trial enrolled the first patient in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional
Indications - Sj&ouml;gren&#8217;s Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our broader development plan includes exploring development of telitacicept in
additional autoantibody-driven diseases where BAFF / APRIL signaling is a validated target, supported by prior clinical experience and mechanistic rationale. This includes Sj&ouml;gren&#8217;s Disease, one of the most common systemic autoimmune
diseases </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
globally, with approximately 870,000 diagnosed patients across key markets, including approximately 290,000 in the United States and approximately 450,000 in the European Union. There are no
approved disease-modifying systemic therapies for the treatment of Sj&ouml;gren&#8217;s Disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telitacicept was evaluated by RemeGen in
a Phase 2 clinical trial in patients with primary Sj&ouml;gren&#8217;s Disease (&#8220;pSD&#8221;) in China. In June 2023, RemeGen presented <FONT STYLE="white-space:nowrap">24-week</FONT> data from its Phase 2 clinical trial in pSD in China which
demonstrated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A statistically significant and clinically meaningful decrease in EULAR Sj&ouml;gren&#8217;s Syndrome Disease
Activity Index scores of 3.8 points (4.3 points placebo-adjusted) from baseline in the telitacicept group, compared to an increase of 0.5 points in the placebo group in the 160mg cohort at week 24. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consistent reduction in IgG, IgA, IgM and B cells. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The overall adverse event rate in the telitacicept group was comparable to that in the placebo group, indicating
telitacicept was well-tolerated. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2025, RemeGen announced that it had achieved the primary endpoint in a
Phase&nbsp;3 clinical trial in China evaluating telitacicept in adults with pSD. The data from the RemeGen-sponsored Phase&nbsp;3 trial conducted in China evaluating telitacicept in pSD were presented at the American College of Rheumatology
(&#8220;ACR&#8221;) Convergence meeting in October 2025. The <FONT STYLE="white-space:nowrap">48-week</FONT> results demonstrated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mean change in ESSDAI score from baseline: At week 24, <FONT STYLE="white-space:nowrap">-4.4</FONT> (160mg), <FONT
STYLE="white-space:nowrap">-3.0</FONT> (80mg), and <FONT STYLE="white-space:nowrap">-0.6</FONT> (placebo); at week 48, <FONT STYLE="white-space:nowrap">-4.6</FONT> (160mg), <FONT STYLE="white-space:nowrap">-3.2</FONT> (80mg), and <FONT
STYLE="white-space:nowrap">-0.4</FONT> (placebo). These data demonstrate durable, dose-dependent improvement in systemic disease activity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mean change in ESSPRI score from baseline: At week 24, <FONT STYLE="white-space:nowrap">-1.88</FONT> (160mg), <FONT
STYLE="white-space:nowrap">-1.31</FONT> (80mg), and <FONT STYLE="white-space:nowrap">-0.36</FONT> (placebo); at week 48, <FONT STYLE="white-space:nowrap">-2.56</FONT> (160mg), <FONT STYLE="white-space:nowrap">-1.74</FONT> (80mg), and <FONT
STYLE="white-space:nowrap">-0.41</FONT> (placebo). These data showed sustained symptomatic benefit in dryness, fatigue, and pain. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">&#8805;3-point</FONT> ESSDAI score improvement: At week 24, 71.8% (160mg), 47.1%
(80mg), and 19.3% (placebo); at week 48, 73.0% (160 mg), 49.1% (80mg), and 16.5% (placebo). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Participants with ESSDAI score &lt;5 (low disease activity): At week 24, 49.6% (160mg), 28.8% (80mg), and 10.9%
(placebo); at week 48, 55.0% (160mg), 32.7% (80mg), and 12.2% (placebo). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Participants with <FONT STYLE="white-space:nowrap">&#8805;1-point</FONT> or &#8805;15% ESSPRI score reduction: At
week 24, 86.2% (160mg), 63.0% (80mg), and 32.2% (placebo); at week 48, 89.1% (160mg), 75.4% (80mg), and 33.3% (placebo). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Change from baseline in <FONT STYLE="white-space:nowrap">MFI-20</FONT> total (fatigue): At weeks 24 and 48,
telitacicept 160mg and telitacicept 80mg each produced a statistically significant reduction in fatigue versus placebo, with improvements sustained through the <FONT STYLE="white-space:nowrap">open-label</FONT> extension period.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Telitacicept demonstrated a favorable safety profile comparable to placebo and consistent with prior studies
across other autoimmune indications, including systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, and IgA nephropathy. No new safety signals were observed. Most adverse events were mild to moderate in severity.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to commence a Phase 3 global clinical trial evaluating telitacicept in patients with pSD in the first half of
2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Appointment of
Chief Medical Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2025, we announced the appointment of Dr.&nbsp;Jeremy Sokolove as Chief Medical Officer.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preliminary Financial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2025, our preliminary unaudited cash and cash equivalents was approximately $160.5&nbsp;million. Subsequent to
September&nbsp;30, 2025, we issued and sold 1,370,111 shares pursuant to our &#8220;at-the-market&#8221; facility that we entered into in December 2022 (the &#8220;ATM Facility&#8221;) with Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, as sales
agent, for net proceeds of $49.8 million. This preliminary financial information reflects our preliminary estimate, based on currently available information. Financial closing procedures for the quarter are not yet completed and final results may
therefore vary from this estimate. Our independent registered public accounting firm, Ernst&nbsp;&amp; Young LLP, has not audited, reviewed, compiled or performed any procedures with respect to the preliminary unaudited financial results as of
September&nbsp;30, 2025. Accordingly, Ernst&nbsp;&amp; Young LLP does not express any opinions or any other forms of assurance with respect thereto. These preliminary unaudited financial results are not comprehensive financial results as of
September&nbsp;30, 2025, should not be viewed as a substitute for complete financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles or more comprehensive financial information, and are not indicative of the
results for any future period. We undertake no obligation to update or revise these amounts as a result of new information or otherwise. Therefore, investors should not place undue reliance on the unaudited preliminary estimated financial
information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
were incorporated under the laws of the State of Delaware in December 2015. Our principal executive offices are located at 500 Boylston Street, Suite 1350, Boston, Massachusetts 02116. Our telephone number is
<FONT STYLE="white-space:nowrap">(617)&nbsp;655-6580.</FONT> Our internet website address is www.vorbio.com. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus
supplement and should not be considered part of this prospectus supplement. Our website address is included in this document as an inactive textual reference only. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS
Act&#8221;). For so long as we remain an emerging growth company, we may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to financial data, including only being required to present two years of audited
financial statements, in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exception from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of
these provisions until we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on the date that is the earliest of: (i)&nbsp;December&nbsp;31, 2026,
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;the last day of the fiscal year in which we have more than $1.235&nbsp;billion in total annual gross revenues, (iii)&nbsp;the date on which we are deemed to be a &#8220;large
accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th, or (iv)&nbsp;the date
on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over the prior <FONT STYLE="white-space:nowrap">three-year</FONT> period. We may choose to take advantage of some but not all of
these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this prospectus supplement. Accordingly, the information contained herein may be different than you might obtain from other public companies in
which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting
standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure
requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging
growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in this prospectus supplement may be different than the information you
may receive from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these elections, which may result in a less active trading market
for our common stock and higher volatility in our share price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#8220;smaller reporting company,&#8221; meaning that the
market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year. We may continue to be a
smaller reporting company if either (i)&nbsp;the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most
recently completed fiscal year and the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth
company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of
audited financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be offered by us </P></TD>
<TD>10,000,000 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares from us </P></TD>
<TD>We have granted the underwriters an option for 30 days from the date of this prospectus supplement to purchase up to an additional 1,500,000 shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering </P></TD>
<TD>16,282,297 shares (or 17,782,297 shares if the underwriters exercise in full their option to purchase additional shares). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that we will receive net proceeds from this offering of approximately $93.7 million, or approximately $107.8 million if the underwriters exercise their option to purchase additional shares in full, after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds of this offering, together with our existing cash, cash equivalents and marketable securities, to advance our clinical development for telitacicept, including initiation of a
Phase&nbsp;3 clinical trial for pSD, as well as manufacturing and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities for telitacicept, and for working capital and general corporate purposes. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section entitled &#8220;Use of Proceeds.&#8221; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#8220;Risk Factors&#8221; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-9</FONT> of this prospectus supplement and under similar headings in other documents incorporated by reference into this prospectus supplement and the
accompanying prospectus for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#8220;VOR&#8221; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock outstanding immediately following this offering set forth above
is based on 6,282,297 shares of common stock outstanding as of June&nbsp;30, 2025, and excludes, as of that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,731,078 shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30,
2025, at a weighted-average exercise price of $25.37 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">886,912&nbsp;shares of common stock issuable upon the exercise of outstanding stock options issued subsequent to
June&nbsp;30, 2025, at a weighted-average exercise price of $40.72 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">96,505 shares of common stock issuable upon vesting and settlement of outstanding restricted stock units as of
June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">882,260&nbsp;shares of common stock issuable upon vesting and settlement of outstanding restricted stock units
issued subsequent to June&nbsp;30, 2025; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,832,384&nbsp;shares of common stock reserved for future issuance under our Amended and Restated 2021 Equity
Incentive Plan (the &#8220;2021 Plan&#8221;) as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2021 Plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">115,932 shares of common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan (the
&#8220;ESPP&#8221;) as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,894,687&nbsp;shares of common stock reserved for future issuance under our 2023 Inducement Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,491,953 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock at
an exercise price of $16.76 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">50,999,999 shares of common stock issuable upon the exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase common stock at an exercise price of $0.002 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale of 1,910,861&nbsp;shares of common stock pursuant to the ATM Facility subsequent to June&nbsp;30, 2025.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares outstanding as of June&nbsp;30, 2025, as well as the number of shares appearing in the bullet
points above, which are excluded from the outstanding share total as of June&nbsp;30, 2025, reflect a retroactive adjustment for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-20</FONT></FONT> reverse stock split
effected on September&nbsp;18, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Up to $125.0&nbsp;million of shares of our common stock were available for sale under our ATM
Facility. As of the date of this prospectus supplement, we have sold approximately $76.1&nbsp;million of shares of our common stock under the ATM Facility. We have agreed not to make any sales under the ATM Facility prior to 30 days from the date of
this prospectus supplement unless the underwriters have exercised their option to purchase additional shares in full and all such additional shares have been issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between June&nbsp;30, 2025 and the date of this prospectus supplement, we have issued an aggregate of 2,145,673 shares of our common stock
pursuant to the cashless exercise of 2,145,829 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of common stock which were outstanding as of June&nbsp;30, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-290490)</FONT> to register the offer and resale of 50,999,999 shares of our common stock issuable upon exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants outstanding as of
June&nbsp;30, 2025 (the &#8220;Resale Registration Statement&#8221;). Once the Resale Registration Statement becomes effective, holders of shares of our common stock issued upon exercise of these <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants (subject to the beneficial ownership limitations on exercise included therein) may elect to sell their shares pursuant to the Resale Registration Statement (other than shares held by our affiliates, which may be subject to the volume
limitations of Rule 144 of the Securities Act), which may cause the market price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average
exercise price of the outstanding stock options described above does not give effect to the previously announced stock option repricing approved by our board of directors on February&nbsp;3, 2025. Unless otherwise indicated, all information in this
prospectus supplement assumes no exercise of the outstanding stock options, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or warrants described above and no exercise of the underwriters&#8217; option to purchase additional shares. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Our business, prospects, financial condition or operating results could be
materially adversely affected by the risks identified below, as well as other risks not currently known to us or that we currently consider immaterial. The trading price of our common stock could decline due to any of these risks, and you may lose
all or part of your investment. Before deciding whether to invest in our common stock, you should consider carefully the risk factors discussed below and those contained in the section entitled &#8220;Risk Factors&#8221; contained in our Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2025, as filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), which is incorporated herein by reference in its entirety, as well as
any amendment or update to our risk factors reflected in subsequent filings with the SEC. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and Ownership of Our
Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will experience immediate and substantial dilution in the book value per share of the common stock you purchase in this
offering and may experience further dilution as a result of outstanding option and warrant exercises, restricted stock unit settlements and future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the price per share of our common stock being offered in this offering is substantially higher than the net tangible book value per share
of our common stock, you will suffer substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. Based on the public offering price of $10.00 per share and our net tangible book deficit as of
June&nbsp;30, 2025, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $76.00 per share with respect to the net tangible book value of the common stock. The exercise of outstanding stock
options and the vesting and settlement of restricted stock units will result in further dilution of your investment. In addition, between June&nbsp;30, 2025 and the date of this prospectus supplement we have issued an aggregate of 2,145,673 shares
of our common stock upon cashless exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase common stock which were outstanding as of June&nbsp;30, 2025, and we expect additional warrant exercises will occur in the near
term. Any exercise of warrants outstanding as of June&nbsp;30, 2025 will result in further dilution of your investment. See the section entitled &#8220;Dilution&#8221; for a more detailed discussion of the dilution you will incur if you purchase
common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may in the future choose to raise capital through offerings of additional shares of our
common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering, including through our ATM Facility. In December 2022, we entered into a sales
agreement with Stifel, pursuant to which we filed a prospectus supplement under which we may sell and issue shares of our common stock having an aggregate offering price of up to $125.0&nbsp;million from time to time in transactions that are deemed
to be an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;at-the-market</FONT></FONT> offering&#8221; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). As of the
date of this prospectus supplement, we had approximately $48.9&nbsp;million remaining for sale under our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> offering program. We have agreed not to make any
sales under the ATM Facility prior to 30 days from the date of this prospectus supplement unless the underwriters have exercised their option to purchase additional shares in full and all such additional shares have been issued. We may sell shares
or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing
stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share of the common stock in this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future issuances or sales of our shares could cause the market price of our common stock to drop significantly, even if our business is
doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares we are selling in this offering may be resold in the public market immediately without restriction, unless
purchased by our affiliates. We and each of our directors, officers and certain stockholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements that, subject to certain exceptions, restrict us and them from selling shares
of our common stock for 60 days (in our case) or 90 days (in the case of our directors, officers and certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders) following this offering, which selling restrictions may be waived, in whole or in part, with or without notice, by J.P. Morgan Securities LLC and Jefferies LLC. Sales of these
shares of common stock are also restricted by securities laws but will become eligible to be sold at various times after the date of this prospectus supplement, unless held by one of our affiliates, in which case the resale of those securities will
be subject to volume limitations under Rule 144 of the Securities Act. As these restrictions on resale end, the market price of our common stock could drop significantly if the holders of those shares sell them or are perceived by the market as
intending to sell them. These declines in our stock price could occur even if our business is otherwise doing well and, as a result, you may lose all or a part of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock has been, and is likely to continue to be, volatile and could be subject to wide fluctuations in response
to various factors. We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-290490)</FONT> to register the offer and resale of 50,999,999 shares of our common
stock issuable upon exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants outstanding as of June&nbsp;30, 2025 (the &#8220;Resale Registration Statement&#8221;). Once the Resale Registration Statement becomes effective, holders of
shares of our common stock issued upon exercise of these <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (subject to the beneficial ownership limitations on exercise included therein) may elect to sell their shares pursuant to the Resale
Registration Statement (other than shares held by our affiliates, which may be subject to the volume limitations of Rule 144 of the Securities Act), which may cause the market price of our common stock to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management will have broad discretion as to the use of the net proceeds from this offering and may not use the proceeds effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes
described in the section entitled &#8220;Use of Proceeds&#8221; on <FONT STYLE="white-space:nowrap">page&nbsp;S-13</FONT> of this prospectus supplement, and you will not have the opportunity as part of your investment decision to assess whether the
net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our
management might not apply our net proceeds in ways that ultimately increase the value of your investment. We intend to use the net proceeds of this offering to advance our clinical development for telitacicept, including initiation of a
Phase&nbsp;3 clinical trial for pSD, as well as manufacturing and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities for telitacicept, and for working capital and general corporate purposes. We may also use a portion of the net
proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement. The
failure by our management to apply these funds effectively could harm our business. Pending their use, we plan to invest the net proceeds from this offering in a variety of capital preservation investments, which may consist of money market funds
and marketable debt securities, including short-term, investment-grade corporate bonds and U.S. Treasury securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this
offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our share price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole
source of gains and you may never receive a return on your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely on an investment in our common stock to
provide dividend income. We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if
any, of our common stock will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_4"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the documents we have filed with the SEC that are incorporated by reference contain &#8220;forward-looking
statements&#8221; within the meaning of Section&nbsp;27A of the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These statements relate to future events or to our future operating or financial
performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by
the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of our clinical trials of our product candidate and preclinical and clinical
trials for any future products candidates, including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become
available and plans with respect to our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any submission of filings for regulatory approval of, and our ability to obtain and maintain
regulatory approvals for, our product candidate and any future product candidates for any indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify patients with the diseases treated by our product candidate and any future product
candidates, and to enroll patients in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the market acceptance and opportunity for and clinical utility of our product
candidate and any future product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the scope of any approved indication for any product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidate or any future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, ongoing losses, future revenue and capital requirements and our need for or
ability to obtain additional funding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations or strategic relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel, including executive officers and members of
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on
commercially reasonable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our intellectual property position for our product candidate or any future
product candidates, and the scope of such protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period over which we estimate our existing cash, cash equivalents and marketable securities will be
sufficient to fund our future operating expenses and capital expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competition or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of our existing resources and the proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue
reliance on our forward-looking statements. Actual results or events </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included
in this prospectus supplement, particularly in the section titled &#8220;Risk Factors,&#8221; that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements
do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You
should read this prospectus supplement and the accompanying prospectus, together with the documents we have filed with the SEC that are incorporated by reference, and any free writing prospectus that we may authorize completely and with the
understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference into this prospectus contain industry,
statistical and market data derived from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this prospectus
supplement and the accompanying prospectus involve a number of assumptions and limitations, and we cannot guarantee the accuracy or completeness of such information. While we are not aware of any misstatements regarding the third-party information
and we believe that each of these surveys, studies and publications is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors. These and other factors could cause results
to differ materially from those expressed in the estimates made by third parties and by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we
believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a
reasonable basis for such statements and our management is responsible for the accuracy of such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry
into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the net proceeds from this offering will be approximately $93.7&nbsp;million (or $107.8&nbsp;million if the underwriters exercise
in full their option to purchase additional shares), after payment of the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities,
to advance our clinical development for telitacicept, including initiation of a Phase 3 clinical trial for pSD, as well as manufacturing and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities for telitacicept, and for working
capital and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with
respect to any acquisitions as of the date of this prospectus supplement.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expected use of net proceeds from this offering represents
our current intentions based on our present plans and business condition. As of the date of this prospectus supplement, we cannot predict with certainty all of the particular uses for the proceeds to be received upon the completion of this offering
or the actual amounts that we will spend on the uses set forth above.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds from this offering, together with our existing
cash, cash equivalents and marketable securities, may not be sufficient for us to fund our preclinical and clinical programs, and we may need to raise additional capital to achieve our business objectives. Based on the planned use of proceeds
described above, we believe that the net proceeds from this offering, together with our current cash, cash equivalents and marketable securities (including the $49.8 million of net proceeds from sales made under our ATM Facility subsequent to
September&nbsp;30, 2025), will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2027. We have based this estimate on assumptions that may prove to be incorrect, and we could
use our available capital resources sooner than we currently expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect that our existing cash, cash equivalents and
marketable securities and the anticipated net proceeds from this offering alone will be sufficient to enable us to fund the completion of the development of our product candidate.&nbsp;The amount and timing of our actual expenditures will depend on
numerous factors, including the results of our research and development efforts, the timing and outcome of any ongoing or future preclinical studies and clinical trials, the timing and outcome of regulatory submissions and any unforeseen cash needs.
As a result, our management will have broad discretion over the use of the proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of the net
proceeds from this offering, we plan to invest the net proceeds from this offering in a variety of capital preservation investments, which may consist of money market funds and marketable debt securities, including short-term, investment-grade
corporate bonds and U.S. Treasury securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchasers of the common stock in this offering will experience immediate and substantial dilution in the net tangible book value per share of
the common stock for accounting purposes. Our net tangible book value, as of June&nbsp;30, 2025, after giving effect to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-20</FONT></FONT> reverse stock split of our common
stock effected on September&nbsp;18, 2025, was approximately $(1,505.7) million, or $(239.67) per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On a pro forma basis, after
giving effect to the issuance and sale of (i)&nbsp;1,910,861 shares of our common stock under our ATM Facility subsequent to June&nbsp;30, 2025 for net proceeds of $69.7&nbsp;million and (ii)&nbsp;2,145,673 shares of our common stock pursuant to the
cashless exercise of 2,145,829 pre-funded warrants to purchase shares of common stock subsequent to June&nbsp;30, 2025 (the &#8220;Pro Forma Adjustments&#8221;), our pro forma net tangible book value would have been approximately
$(1,436.0)&nbsp;million, or $(138.89) per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of the shares in this offering and further assuming the
receipt of the estimated net proceeds of $93.7 million (after deducting underwriting discounts and commissions and estimated offering expenses payable by us), our pro forma as adjusted net tangible book value as of June&nbsp;30, 2025, would have
been approximately $(1,342.4) million, or $(66.00) per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates the per share dilution to new investors
purchasing shares in this offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(239.67)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to the Pro Forma Adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share as of June 30, 2025, before this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(138.89)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors purchasing shares of
common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share as of June&nbsp;30, 2025, after giving
effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(66.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares of common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase up to 1,500,000 additional shares of common
stock, at the public offering price of $10.00&nbsp;per share, the pro forma as adjusted net tangible book value after this offering would be $(60.82) per share, representing an increase in net tangible book value of $78.07 per share to existing
stockholders and immediate dilution in net tangible book value of $70.82 per share to investors purchasing our common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus supplement, we had an aggregate of 48,854,170 <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants
and 3,491,953 warrants to purchase shares of our common stock outstanding. If the holders of these securities were to cash exercise in full their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and warrants (without giving effect to any
beneficial ownership limitations on exercise included therein), as applicable, our pro forma as adjusted net tangible book value after this offering would be $(17.66) per share, representing an increase in net tangible book value of $48.34 per share
to existing stockholders and immediate dilution in net tangible book value of $27.66 per share to investors purchasing our common stock in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion is based on 6,282,297 shares of common stock outstanding as of
June&nbsp;30, 2025 and excludes, as of that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,731,078 shares of common stock issuable upon the exercise of outstanding stock options as of June&nbsp;30,
2025, at a weighted-average exercise price of $25.37 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">886,912&nbsp;shares of common stock issuable upon the exercise of outstanding stock options issued subsequent to
June&nbsp;30, 2025, at a weighted-average exercise price of $40.72 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">96,505 shares of common stock issuable upon vesting and settlement of outstanding restricted stock units as of
June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">882,260&nbsp;shares of common stock issuable upon vesting and settlement of outstanding restricted stock units
issued subsequent to June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,832,384&nbsp;shares of common stock reserved for future issuance under the 2021 Plan as well as any automatic
increases in the number of shares of common stock reserved for future issuance under the 2021 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">115,932&nbsp;shares of common stock reserved for future issuance under the ESPP as well as any automatic
increases in the number of shares of common stock reserved for future issuance under the ESPP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,894,687&nbsp;shares of common stock reserved for future issuance under our 2023 Inducement Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,491,953 shares of common stock issuable upon the exercise of outstanding warrants to purchase common stock at
an exercise price of $16.76; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">48,854,170 shares of common stock issuable upon the exercise of outstanding
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase common stock at an exercise price of $0.002 per share. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares outstanding as of June&nbsp;30, 2025, as well as the number of shares appearing in the bullet points above, which are
excluded from the outstanding share total as of June&nbsp;30, 2025, reflect a retroactive adjustment for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-20</FONT></FONT> reverse stock split effected on September&nbsp;18,
2025. To the extent that outstanding options, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and warrants are exercised or outstanding restricted stock units vest and settle, you will experience further dilution. We may choose to raise
additional capital due to market conditions or strategic considerations even if at that time we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or
convertible debt securities, the issuance of these securities will result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_7"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary describes the material U.S. federal income tax consequences
of the ownership and disposition of our common stock acquired in this offering <FONT STYLE="white-space:nowrap">by&nbsp;Non-U.S.&nbsp;Holders</FONT> (as defined below). This discussion is not a complete analysis of all potential U.S. federal income
tax consequences relating thereto, does not deal <FONT STYLE="white-space:nowrap">with&nbsp;non-U.S.,&nbsp;state,</FONT> or local consequences that may be relevant <FONT STYLE="white-space:nowrap">to&nbsp;Non-U.S.&nbsp;Holders</FONT> in light of
their particular circumstances, and does not address U.S. federal tax consequences (such as gift and estate taxes) other than income taxes. In particular, this discussion does not address any alternative minimum tax, the Medicare contribution tax on
net investment income, or the application of special tax accounting rules under Section&nbsp;451(b) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). Special rules different from those described below may apply to <FONT
STYLE="white-space:nowrap">certain&nbsp;Non-U.S.&nbsp;Holders</FONT> that are subject to special treatment under the Code, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt&nbsp;organizations</FONT> or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified&nbsp;retirement</FONT> plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers and traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and
corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations organized outside of the United States, any state thereof, or the District of Columbia that are
nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion
transaction,&#8221; &#8220;synthetic security,&#8221; or integrated investment or other risk reduction strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire our common stock through the exercise of an option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our common stock pursuant to the exercise of warrants or conversion rights under
convertible instruments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;qualified foreign pension funds&#8221; as defined in Section&nbsp;897(l)(2) of the Code and entities all
of the interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships and other pass-through entities or arrangements treated as partnerships, S corporations, or
disregarded entities for U.S. federal income tax purposes and investors in such entities or arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such holders are urged to consult their own tax advisors to determine the U.S. federal, state, and local, <FONT
STYLE="white-space:nowrap">non-U.S.,</FONT> and other tax consequences that may be relevant to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below is based upon
the provisions of the Code, the Treasury Regulations promulgated thereunder, published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#8220;IRS&#8221;) and judicial decisions, each as of the date hereof, and
such authorities may be repealed, revoked, or modified, or interpreted differently, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have not requested, and will not request, a
ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assurance that the IRS or a court will agree with such statements and conclusions. This discussion assumes that <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> holds our
common stock as a &#8220;capital asset&#8221; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal
income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Partnerships holding our common stock and the partners
in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PERSONS CONSIDERING THE PURCHASE OF OUR COMMON STOCK PURSUANT TO THIS OFFERING
SHOULD CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME, GIFT, ESTATE, AND OTHER TAX CONSEQUENCES OF ACQUIRING, OWNING, AND DISPOSING OF OUR COMMON STOCK IN LIGHT OF THEIR PARTICULAR SITUATIONS AS WELL AS ANY CONSEQUENCES ARISING
UNDER THE LAWS OF ANY OTHER TAXING JURISDICTION, INCLUDING ANY STATE, LOCAL, <FONT STYLE="white-space:nowrap">OR&nbsp;NON-U.S.&nbsp;TAX</FONT> CONSEQUENCES, OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, <FONT STYLE="white-space:nowrap">a&nbsp;&#8220;Non-U.S.&nbsp;Holder&#8221;</FONT> is a beneficial owner of
our common stock that is neither a U.S. Holder (as defined below) nor a partnership (or other entity or arrangement treated as a partnership for U.S. federal income tax purposes). A &#8220;U.S. Holder&#8221; means a beneficial owner of our common
stock that is, for U.S. federal income tax purposes, any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized
in or under the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more
United States persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable Treasury Regulations to be treated as
a United States person. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we make distributions of cash or property on our common stock to <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder,</FONT> such
distributions, to the extent made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), generally will constitute dividends for U.S. federal income tax purposes and will be subject to
withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty, subject to the discussions below regarding effectively connected income, backup withholding, and foreign accounts. To obtain a reduced rate of
withholding under a treaty, <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> generally will be required to provide us and/or our paying agent with a properly executed IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN&nbsp;(in</FONT> the case of individuals) or IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E&nbsp;(in</FONT></FONT> the case of entities), or other appropriate
form, before the payment of such dividend certifying <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder&#8217;s</FONT> entitlement to benefits under that treaty. If <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> is
eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and does not timely provide us and/or our paying agent with the required certification, such&nbsp;Non-U.S.&nbsp;Holder may be able to obtain a refund or credit of
any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If dividends paid to <FONT
STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> are effectively connected with <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder&#8217;s</FONT> conduct of a trade or business within the United States (and, if required by
an applicable income tax treaty, are attributable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a permanent establishment or fixed base that such holder maintains in the United States), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal
withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to us and/or our paying agent a properly executed IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI,&nbsp;stating</FONT> that the dividends are so connected. In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates
applicable to U.S. residents. A <FONT STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holder</FONT> receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax,&#8221; which is imposed, under
certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the <FONT STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holder&#8217;s</FONT> effectively connected earnings and profits, subject
to certain <FONT STYLE="white-space:nowrap">adjustments.&nbsp;Non-U.S.&nbsp;Holders</FONT> should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent distributions on our common stock exceed our current and accumulated earnings and profits, such distributions will first reduce <FONT
STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder&#8217;s</FONT> adjusted basis in our common stock, but not below zero, and then will be treated as capital gain to the extent of any amount distributed in excess of such holder&#8217;s
adjusted tax basis in our common stock. Such capital gain generally will be taxed in the same manner as gain realized from a sale or other disposition of common stock, as described in the next section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on disposition of our common stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and foreign accounts,
<FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with a trade or business of such holder in the United States (and, if required
by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in the United States); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> is a nonresident alien individual and is
present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met; or</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are or have been a &#8220;United States real property holding corporation&#8221; within the meaning of
Section&nbsp;897(c)(2) of the Code at any time within the shorter of the five-year period preceding such disposition or such holder&#8217;s holding period in our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, we would be a United States real property holding corporation if the fair market value of our U.S. real property interests equals
or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business. We believe that we are not, and we do not anticipate becoming, a United States real
property holding corporation, but there can be no assurance in this regard. Even if we are treated as a United States real property holding corporation, gain realized by <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> on a
disposition of our common stock will not be subject to U.S. federal income tax so long as <FONT STYLE="white-space:nowrap">(1)&nbsp;the&nbsp;Non-U.S.&nbsp;Holder</FONT> owned, directly, indirectly, and constructively, no more than 5% of our common
stock at all times within the shorter of (i)&nbsp;the five-year period preceding the disposition or (ii)&nbsp;the holder&#8217;s holding period in our common stock and (2)&nbsp;our common stock is &#8220;regularly traded,&#8221; as defined by
applicable Treasury Regulations, on an established securities market. There can be no assurance that our common stock will qualify as regularly traded on an established securities market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A&nbsp;Non-U.S.&nbsp;Holder</FONT> described in the first bullet&nbsp;above will be required to pay tax on a
net income basis at the U.S. federal income tax rates applicable to U.S. Holders, and <FONT STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holders</FONT> described in the first bullet&nbsp;above may be subject to the additional branch
profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty, as adjusted for certain items. <FONT STYLE="white-space:nowrap">A&nbsp;Non-U.S.&nbsp;Holder</FONT> described in the second bullet&nbsp;above will be
subject to U.S. federal income tax at a flat 30% rate (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which gain may be offset by certain U.S.-source capital losses (even
though <FONT STYLE="white-space:nowrap">such&nbsp;Non-U.S.&nbsp;Holder</FONT> is not considered a resident of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States), provided that <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> has timely filed U.S. federal income tax returns with respect to such <FONT
STYLE="white-space:nowrap">losses.&nbsp;Non-U.S.&nbsp;Holders</FONT> should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information reporting requirements and backup withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns are required to be filed with the IRS in connection with payments of distributions on our common stock, regardless of
whether such distributions constitute dividends or whether any tax was actually withheld. Unless <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> complies with certification procedures to establish that <FONT
STYLE="white-space:nowrap">such&nbsp;Non-U.S.&nbsp;Holder</FONT> is not a United States person, information returns may also be filed with the IRS in connection with the proceeds from a sale or other disposition of our common stock. <FONT
STYLE="white-space:nowrap">A&nbsp;Non-U.S.&nbsp;Holder</FONT> may be subject to backup withholding, currently at a rate of 24%, on payments on our common stock or on the proceeds from a sale or other disposition of our common stock, unless <FONT
STYLE="white-space:nowrap">such&nbsp;Non-U.S.&nbsp;Holder</FONT> complies with certification procedures to establish that <FONT STYLE="white-space:nowrap">such&nbsp;Non-U.S.&nbsp;Holder</FONT> is not a United States person or otherwise establishes
an exemption, provided that the applicable withholding agent does not have actual knowledge or reason to know that <FONT STYLE="white-space:nowrap">such&nbsp;Non-U.S.&nbsp;Holder</FONT> is a United States person.
<FONT STYLE="white-space:nowrap">A&nbsp;Non-U.S.&nbsp;Holder</FONT> may avoid backup withholding by providing a properly executed applicable IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8&nbsp;certifying</FONT>
<FONT STYLE="white-space:nowrap">its&nbsp;non-U.S.&nbsp;status.</FONT> <FONT STYLE="white-space:nowrap">Non-U.S.&nbsp;Holders</FONT> should consult their tax advisors regarding the application of the information reporting and backup withholding
rules to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Copies of information returns may be made available to the tax authorities of the country in which <FONT
STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> resides or is incorporated under the provisions of a specific treaty or agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts withheld under the backup withholding rules are not additional taxes and may be refunded to
<FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> or credited against its U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign accounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sections 1471 through
1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain payments to a foreign financial institution (as specifically defined by applicable rules) unless such institution enters into an agreement with
the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well
as certain account holders that are foreign entities with U.S. owners). FATCA also generally imposes a U.S. federal withholding tax of 30% on certain payments to <FONT STYLE="white-space:nowrap">a&nbsp;non-financial&nbsp;foreign</FONT> entity unless
such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the entity. An
intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. The withholding tax described above will not apply if the foreign financial institution
<FONT STYLE="white-space:nowrap">or&nbsp;non-financial&nbsp;foreign</FONT> entity otherwise qualifies for an exemption from the rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FATCA withholding currently applies to dividends paid on our common stock. FATCA withholding would have applied to the gross proceeds of a
disposition of our common stock, but the U.S. Treasury Department has released proposed regulations which, if finalized in their present form, would eliminate the U.S. federal withholding tax of 30% that otherwise would apply to the gross proceeds
of a disposition of our common stock. In its preamble to such proposed regulations, the U.S. Treasury Department stated that taxpayers may generally rely on the proposed regulations until final regulations are
<FONT STYLE="white-space:nowrap">issued.&nbsp;Non-U.S.&nbsp;Holders</FONT> are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR COMMON STOCK,
INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_8"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering the shares of common stock described in this prospectus supplement through a number of underwriters. J.P. Morgan Securities
LLC, Jefferies LLC, Citigroup Global Markets Inc. and TD Securities (USA) LLC are acting as joint <FONT STYLE="white-space:nowrap">book-running</FONT> managers of the offering and as representatives of the underwriters. We have entered into an
underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the
underwriting discounts and commissions set forth on the cover page of this prospectus supplement, the number of shares of common stock listed next to its name in the following table: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are committed to purchase all the common shares offered by us if they purchase any shares.
The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters propose to offer the common shares directly to the public at the public offering price set forth on the cover page of this
prospectus supplement and to certain dealers at that price less a concession not in excess of $0.36 per share. After the initial offering of the shares to the public, if all of the common shares are not sold at the initial public offering price, the
underwriters may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have an option to buy up to 1,500,000 additional shares of common stock from us to cover sales of shares by the underwriters
which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus supplement to exercise this option to purchase additional shares. If any shares are purchased with this option to
purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same
terms as those on which the shares are being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting fee is equal to the public offering price per share of common
stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $0.60 per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming
both no exercise and full exercise of the underwriters&#8217; option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With full<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of this offering, including registration, filing and
listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $350,000. The underwriters have agreed to reimburse us for certain expenses incurred in connection with
this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement in electronic format may be made available on the web sites maintained by one or more
underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet
distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that we will not (i)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase, loan, hedge, make any short sale
or otherwise transfer or dispose of, directly or indirectly, or file with or confidentially submit to the Securities and Exchange Commission a registration statement under the Securities Act relating to, any shares of our common stock or securities
convertible into or exercisable or exchangeable for any shares of our common stock, (ii)&nbsp;enter into any hedging, swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any shares of common
stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), or (iii)&nbsp;publicly disclose the intention to do any
of the foregoing, in each case without the prior written consent of J.P. Morgan Securities LLC and Jefferies LLC for a period of 60 days after the date of this prospectus supplement, other than the shares of our common stock to be sold in this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions on our actions, as described above, do not apply to certain transactions, including (i)&nbsp;shares of our
common stock sold pursuant to this prospectus supplement, (ii)&nbsp;any shares of our common stock or any securities or other awards (including without limitation options, restricted stock or restricted stock units) convertible into, exercisable
for, or that represent the right to receive, shares of our common stock pursuant to any stock option plan, incentive plan or stock purchase plan of ours or otherwise in equity compensation arrangements that are described in this prospectus
supplement, provided that any directors or officers who are the recipients thereof have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters, (iii)&nbsp;any shares of our common stock issued upon the
conversion, exercise or exchange of convertible, exercisable or exchangeable securities outstanding as of the date of this prospectus supplement, in each case if such convertible, exercisable or exchangeable securities are described in this
prospectus supplement, provided that any directors or officers who are the recipients thereof have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters, (iv)&nbsp;the filing by us of any registration
statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to any stock option plan, incentive plan or stock purchase plan of ours that are described in this prospectus supplement, (v)&nbsp;any shares of our common stock or any
securities convertible into or exchangeable for, or that represent the right to receive, shares of our common stock issued in connection with any joint venture, commercial or collaborative relationship or the acquisition or license by us of the
securities, businesses, property or other assets of another person or entity or pursuant to any employee benefit plan assumed by us in connection with any such acquisition, provided that any shares of our common stock issued in connection with any
such acquisition do not exceed 5% of the total number of shares of our common stock issued and outstanding as of the date of this prospectus supplement and provided further that the recipients thereof have entered into
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters, (vi)&nbsp;beginning on the earlier of 30 days after the date of this prospectus supplement or the exercise in full of the underwriters&#8217; option to buy additional
shares in this offering (the &#8220;ATM Lockup Expiration&#8221;), shares of our common stock sold under our ATM Facility, and (vii)&nbsp;if the prospectus supplement relating to the ATM Facility is terminated in connection with this offering, the
filing of&nbsp;a prospectus supplement to the Registration Statement to which this prospectus supplement relates on or after the ATM Lockup Expiration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers and certain stockholders (such persons, the <FONT STYLE="white-space:nowrap">&#8220;lock-up</FONT>
parties&#8221;) have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited
exceptions, for a period of 90&nbsp;days after the date of this prospectus supplement (such period, the &#8220;restricted period&#8221;), may not (and may not cause any of their direct or indirect affiliates to), without
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the prior written consent of J.P. Morgan Securities LLC and Jefferies LLC, (i)&nbsp;offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any shares of
our common stock, or any options or warrants to purchase any shares of our common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of our common stock, (ii)&nbsp;engage in any hedging or other
transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument) which is designed
to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or someone other than the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party), or transfer of any of the economic consequences of ownership, any of the economic consequences of ownership of any shares of common stock or any such other securities (regardless of whether any
of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), or (iii)&nbsp;publicly disclose the intention to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements between the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including (a)&nbsp;transfers of
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities: (i)&nbsp;as a bona fide gift or gifts or as a charitable contribution, (ii)&nbsp;to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party
or the immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a beneficiary of the trust or to the estate of the beneficiary of such trust,
(iii)&nbsp;in connection with the sale of shares of our common stock (a)&nbsp;acquired pursuant to this prospectus supplement or (b)&nbsp;acquired in open market transactions after this offering, (iv)&nbsp;if the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party is a corporation, partnership, limited liability company, trust or other business entity (a)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity
that is an affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlled or managed by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or affiliates of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party, or (b)&nbsp;as part of a distribution, transfer or disposition without consideration by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party to its stockholders, partners, members, beneficiaries
or other equity holders, (v)&nbsp;to us in connection with the exercise, vesting, exchange or settlement of options, warrants or other rights to acquire shares of our common stock, including any security convertible into, exchangeable for or that
represent the right to receive shares of our common stock pursuant to an employee benefit plan, option, warrant or other right described in this prospectus supplement, provided that any such shares issued upon exercise, vesting, exchange or
settlement of such option, warrant, restricted stock unit or other right shall be subject to the restrictions on transfer set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (vi)&nbsp;by will or intestacy, (vii)&nbsp;to an
immediate family member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, (viii)&nbsp;by operation of law or pursuant to a court order or a settlement agreement related to the distribution of assets in connection with the dissolution of
a marriage, domestic partnership or civil union, (ix)&nbsp;to us pursuant to agreements under which we have (a)&nbsp;the option to repurchase such securities or (b)&nbsp;a right of first refusal with respect to transfers of such securities, in each
case upon termination of service of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or (x)&nbsp;under a trading plan established pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act that is existing as of
the date of this prospectus supplement; (b)&nbsp;the establishment by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that such plan
does not provide for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period; and (c)&nbsp;the sale, disposal or transfer of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s shares of
common stock or any options or warrants to purchase any shares of our common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of our common stock to a bona fide third party pursuant to a
tender offer for securities of ours or any merger, consolidation or other business combination involving a change of control of us occurring after the consummation of this offering, that, in each case, has been approved by our board of directors,
and provided that all of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s shares of common stock or any options or warrants to purchase any shares of our common stock, or any securities convertible into, exchangeable for or that
represent the right to receive shares of our common stock subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that are not so transferred, sold, tendered or otherwise disposed of remain subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement, and provided, further, that it will be a condition of transfer, sale, tender or other disposition that if such tender offer or other transaction is not completed, any of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s shares of common stock or any options or warrants to purchase any shares of our common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares
of our common stock remain subject to the restrictions on transfer set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC and Jefferies LLC, in their sole discretion, may release the
securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters described above, in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;VOR&#8221;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and
selling shares of common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of
common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short
sales. Short sales may be &#8220;covered&#8221; shorts, which are short positions in an amount not greater than the underwriters&#8217; option to purchase additional shares referred to above, or may be &#8220;naked&#8221; shorts, which are short
positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this
determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A
naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the
extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act of 1933, they may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty
bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this
offering to repay the underwriting discount received by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These activities may have the effect of raising or maintaining the market
price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters
commence these activities, they may discontinue them at any time. The underwriters may carry out these transactions on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time
to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees
and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions
in our debt or equity securities or loans, and may do so in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than in the United States, no action has been taken by us
or the underwriters that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or
sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under
circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus
supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each a &#8220;Member State&#8221;), no shares of common stock have been offered
or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares of common stock which has been approved by the competent authority in that Member State or, where
appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of shares of common stock may be made to the public in that Member State
at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to any legal entity which is a qualified investor as
defined under the Prospectus Regulation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined under
the Prospectus Regulation), subject to obtaining the prior consent of the representative for any such offer; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) in any other
circumstances falling within Article 1(4) of the Prospectus Regulation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided that no such offer of the shares of common stock shall
require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires our shares of common stock
or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and us that it is a &#8220;qualified investor&#8221; within the meaning of Article 2(e) of the Prospectus Regulation. In
the case of the shares of common stock being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of
common stock acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which
may give rise to an offer of the shares of common stock to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to
each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation
to the shares of common stock in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares of common stock to be offered so as to enable an investor to decide to
purchase or subscribe for the shares of common stock, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
relation to the United Kingdom, no shares of common stock have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares of common stock that
either (i)&nbsp;has been approved by the Financial Conduct Authority, or (ii)&nbsp;is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional provision in Regulation 74 of the Prospectus
(Amendment etc.) (EU Exit) Regulations 2019, except that offers of shares of common stock may be made to the public in the United Kingdom at any time under the following exemptions under the UK Prospectus Regulation: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to any legal entity which is a qualified investor as defined in Article 2 of the UK Prospectus Regulation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined in
Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representative for any such offer; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) in
any other circumstances falling within section 86 of the Financial Services and Markets Act 2000, as amended, or the FSMA, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided that
no such offer of shares of common stock shall require the issuer or any underwriter to publish a prospectus pursuant to section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the shares of common stock in the
United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of
common stock, and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. We have not authorized and do not authorize the making of
any offer of shares of common stock through any financial intermediary on their behalf, other than offers made by the underwriters with a view to the final placement of the shares of common stock as contemplated in this prospectus supplement.
Accordingly, no purchaser of the shares of common stock, other than the underwriters, is authorized to make any further offer of the shares of common stock on behalf of us or the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#8220;qualified investors&#8221; (as defined in Article&nbsp;2 of the UK Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#8220;Order&#8221;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article
49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the securities in the United
Kingdom within the meaning of the FSMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on the
information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares
of common stock may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or
subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of
the shares of common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement does not constitute an offer to the public or a solicitation to purchase or invest in any shares of our common
stock. No shares of our common stock have been offered or will be offered to the public in Switzerland, except that offers of shares of our common stock may be made to the public in Switzerland at any time under the following exemptions under the
Swiss Financial Services Act (&#8220;FinSA&#8221;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to any person which is a professional client as defined under the FinSA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) in any other circumstances falling within Article 36 FinSA in connection with Article 44 of the Swiss Financial Services Ordinance, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares of our common stock shall require us or any investment bank to publish a prospectus pursuant to Article
35 FinSA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common stock have not been and will not be listed or admitted to trading on a trading venue in Switzerland.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the shares of our common stock constitutes a prospectus as
such term is understood pursuant to the FinSA and neither this document nor any other offering or marketing material relating to the shares of our common stock may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571) of
Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the
meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is
directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common stock which are or are intended to
be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Singapore SFA Product Classification&#8212;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise
specified before an offer of shares of common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares of common stock are &#8220;prescribed capital markets products&#8221;
(as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice
<FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each representative has acknowledged
that this prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, each representative has represented and agreed that it has not offered or sold any shares of common stock or caused the
shares of common stock to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares of common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock or cause the shares of common stock to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this
prospectus supplement or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock, whether directly or indirectly, to any person in Singapore other than: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or
amended from time to time, or the SFA) pursuant to Section&nbsp;274 of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) to a relevant person (as defined in
Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares of common stock are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold
investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as
defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares
of common stock pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) to an institutional investor or to a relevant
person, or to any person arising from an offer referred to in Section&nbsp;276(4)(i)(B) of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii) where no consideration is or will
be given for the transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii) where the transfer is by operation of law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv) as specified in Section&nbsp;276(7) of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">v) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities based Derivatives
Contracts) Regulations 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and
Exchange Act. Accordingly, none of the shares of common stock, nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used herein means any
person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a
resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in
effect at the relevant time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United Arab Emirates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates
(including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus
supplement and the accompanying prospectus do not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus supplement and the
accompanying prospectus have not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP, New York, New York, will pass upon the validity of the issuance of the shares being sold in this offering. Certain legal matters
relating to this offering will be passed upon for the underwriters by Paul Hastings LLP, New York, New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this
prospectus supplement, GC&amp;H Investments, LLC and GC&amp;H Investments, a California partnership, which are entities beneficially owned by current and former partners and associates of Cooley LLP, beneficially hold an aggregate of 1,767 shares of
our common stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about the
Company&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus supplement. Our financial statements are incorporated by reference in
reliance on Ernst&nbsp;
&amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_11"></A>WHERE YOU
CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
under the Securities Act with respect to the shares of common stock we are offering under this prospectus supplement. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration
statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed
as a part of the registration statement. We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other
information regarding issuers that file electronically with the SEC, including Vor Biopharma. The SEC&#8217;s website can be found at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also request a copy of these filings, at no cost, by writing us at 500 Boylston Street, Suite 1350, Boston, Massachusetts 02116, or
calling us at (617) <FONT STYLE="white-space:nowrap">655-6580.</FONT> We also maintain a website at www.vorbio.com, at which you may access these materials free of charge after they are electronically filed with, or furnished to, the SEC. The
information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus supplement or the accompanying prospectus. We have included our website address as an inactive textual
reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc89411_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important
information to you by referring you to those documents. Information incorporated by reference is part of this prospectus supplement and the accompanying prospectus. Later information filed with the SEC will update and supersede this information. The
SEC&#8217;s Internet site can be found at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference the documents listed below and any future
filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement until the termination of the offering of the shares covered by this prospectus supplement (other than portions of
Current Reports furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, or are
otherwise not incorporated into registration statements pursuant to applicable rules promulgated by the SEC): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025042623/vor-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;20, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;
31, 2024 from our Revised Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525107123/d74158ddefr14a.htm">Schedule 14A</A>, filed with the SEC on April&nbsp;30, 2025;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2025 and June&nbsp;30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025071349/vor-20250331.htm">May&nbsp;
14, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025107276/vor-20250630.htm">August&nbsp;12, 2025</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525003259/d861124d8k.htm">January&nbsp;8,
 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525021763/d921842d8k.htm">February&nbsp;
6, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525072340/d932261d8k.htm">April&nbsp;
3, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525096692/d898205d8k.htm">April&nbsp;
25, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525115554/d924194d8k.htm">May&nbsp;
8, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525123141/d927316d8k.htm">May&nbsp;
20, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525125833/d95113d8k.htm">May&nbsp;
23, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525147339/d27026d8k.htm">June&nbsp;
26, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525157638/d933755d8k.htm">July&nbsp;
10, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525162644/d24616d8k.htm">July&nbsp;
22, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525189169/d24419d8k.htm">August&nbsp;
27, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525189435/d939901d8k.htm">August&nbsp;
27, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525205553/d945826d8k.htm">September&nbsp;
17, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525261723/vor-20251102.htm">November&nbsp;3, 2025</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in <A HREF="http://www.sec.gov/Archives/edgar/data/1817229/000095017025042623/vor-ex4_3.htm">Exhibit
 4.3</A> to our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025042623/vor-20241231.htm"><FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A> for the year ended
December&nbsp;31, 2024, filed with the SEC on March&nbsp;20, 2025, and including any amendments and reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to each person, including any beneficial owners, to whom a prospectus is delivered, upon written or oral
request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You should direct any requests for documents by writing us at 500 Boylston Street, Suite 1350, Boston, Massachusetts 02116 or
telephoning us at <FONT STYLE="white-space:nowrap">(617)&nbsp;655-6580.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Rule 412 of the Securities Act, any
statement contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by
reference herein modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g89411g65s86.jpg" ALT="LOGO" STYLE="width:3.69449in;height:1.32085in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$350,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">From time to time, we may offer and sell up to $350,000,000 of any combination of the securities described in this prospectus in one or more
offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of
the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may
also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before
you invest in any of the securities being offered. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting
company&#8221; under the federal securities laws and, as such, are subject to reduced public company reporting requirements. See &#8220;Summary&#8212;Implications of Being an Emerging Growth Company and Smaller Reporting Company.&#8221; </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Our common stock is traded on The Nasdaq Global Select Market under the symbol &#8220;VOR.&#8221; On March&nbsp;18, 2025, the last reported
sales price of our common stock was $0.8265&nbsp;per share.<B> </B>The applicable prospectus supplement will contain information, where applicable, as to any other listing on The Nasdaq Global Select Market or any securities market or other exchange
of the securities, if any, covered by the prospectus supplement. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We will sell these securities directly to investors, through agents
designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#8220;Plan of Distribution&#8221; in this
prospectus and in the applicable prospectus supplement. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable
fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus
supplement. </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B></B><B><I>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described
under the heading &#8220;<A HREF="#tx89411_3">Risk Factors</A>&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference
into this prospectus.</I></B><B> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is March&nbsp;31, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx89411_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities
and Exchange Commission (the &#8220;SEC&#8221;), utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration statement, we may sell any combination of the securities described in this prospectus in one or more offerings up to
a total aggregate offering price of $350,000,000. This prospectus provides you with a general description of the securities we may offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the
terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we
may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus
supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information By Reference,&#8221; before investing in any of the
securities offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS
SUPPLEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information that we have provided or incorporated by reference in this prospectus, any
applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those
contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not
contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not
constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus
constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing
prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even
though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated herein by reference contain summaries of certain provisions contained in some of the
documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed,
will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More
Information.&#8221; </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in
making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading
&#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also
carefully read the information incorporated by reference into this prospectus, including our financial statements and related notes, and the exhibits to the registration statement of which this prospectus is a part, before making your investment
decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, as used in this prospectus, the terms the &#8220;Company,&#8221; &#8220;Vor
Biopharma,&#8221; &#8220;Vor Bio,&#8221; &#8220;Vor,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to Vor Biopharma Inc., a Delaware corporation, and its consolidated subsidiary,
and &#8220;our board of directors&#8221; refers to the board of directors of Vor Biopharma Inc. &#8220;VOR BIOPHARMA&#8221; and the Vor Biopharma logo and other trademarks, trade names or service marks of Vor Biopharma Inc. appearing in this
prospectus are the property of Vor Biopharma Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
company harnessing the power of cell and genome engineering to develop potentially transformative therapies in acute myeloid leukemia (&#8220;AML&#8221;), a devastating disease with few treatment options. AML is the most common type of acute
leukemia in adults and one of the deadliest and most aggressive blood cancers, affecting approximately 20,000 newly diagnosed patients each year in the United&nbsp;States. Leveraging our expertise in hematopoietic stem cell (&#8220;HSC&#8221;)
biology and genome engineering, we genetically modify HSCs to remove surface targets and then provide these cells as hematopoietic cell transplants to patients. Once these cells engraft into bone marrow, the patient&#8217;s healthy cells are
shielded because they no longer express the surface target, leaving only the cancerous cells exposed. We believe this will unlock the potential of targeted therapies to selectively destroy cancerous cells while shielding healthy cells. As a result,
our shielded transplants are designed to limit <FONT STYLE="white-space:nowrap">the&nbsp;on-target&nbsp;toxicities</FONT> associated with these targeted therapies, thereby enhancing their utility, and broadening their applicability. We intend to
pair our shielded transplants with targeted therapeutics such as antibody drug conjugates or VCAR33, a chimeric antigen receptor T cell therapy designed to target CD33, to bring potentially transformative outcomes to patients and establish a new
standard of care Treatment System in AML. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information concerning the Company is contained in the documents that we file with the SEC, as a reporting company under the Securities
Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which are accessible at www.sec.gov. Our website address is www.vorbio.com. The information contained on, or that can be accessed through, our website is not a part of this
prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock. We have included our website address in this prospectus solely as an inactive textual reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mailing address is 100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140. Our telephone number is <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-655-6580.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and Smaller
Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012
(&#8220;JOBS Act&#8221;). For so long as we remain an emerging growth company, we may take advantage of relief </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from certain reporting requirements and other obligations that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to financial data, including only being required to present two years of audited
financial statements, in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exception from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the
communication of critical audit matters in the auditor&#8217;s report on financial statements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of
these provisions until we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on the date that is the earliest of: (i)&nbsp;December&nbsp;31, 2026, (ii) the last day of the fiscal year in which we
have more than $1.07&nbsp;billion in total annual gross revenues, (iii)&nbsp;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over the
prior three-year period. We may choose to take advantage of some but not all of these reduced reporting requirements. We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein
may be different than you might obtain from other public companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act,
emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the extended transition period to comply with new or revised
accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised
accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these elections, the information that we provide in
this prospectus may be different than the information you may receive from other public companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive as a result of these
elections, which may result in a less active trading market for our common stock and higher volatility in our share price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a
&#8220;smaller reporting company,&#8221; meaning that the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million and our annual revenue was less than $100&nbsp;million during the most
recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&nbsp;the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million or (ii)&nbsp;our annual
revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million. If we are a smaller reporting
company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose
to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination, up to a total aggregate offering price of $350,000,000 from time to time in
one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This
prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and
other important terms of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">important United States federal income tax considerations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the
time of the effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to
consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors
or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in
the applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those underwriters or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimated net proceeds to us. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock</I></B>. We may issue shares of our common stock from time to time. The
holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares
of preferred stock, the holders of our common stock are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common
stock are entitled to share ratably in all net assets remaining after payment of all of our debts and other liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Our common stock does not carry any preemptive
rights enabling a holder to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock</I></B>. We may issue shares of our preferred stock from time to time, in one or more series. Under our Amended and
Restated Certificate of Incorporation (the &#8220;Restated Certificate&#8221;), our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or the rules of any
stock exchange or market on which our securities are then traded), to designate up to 10,000,000 shares of preferred stock in one or more series and to determine the designations, voting powers, preferences and rights of each series of the preferred
stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares
constituting any series or the designation of any series, any or all of which may be greater than the rights of the common stock. Any convertible preferred stock we may issue will be convertible into our common stock or exchangeable for our other
securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. You should refer to our Restated Certificate and our Bylaws, both of which are included as exhibits to documents incorporated by
reference in the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell any series of preferred stock under this
prospectus, we will fix the designations, voting powers, preferences and rights of such series of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will
file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of
preferred stock that we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the
series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Securities</I></B>. We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or
as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the
manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or preferred stock. Conversion may be mandatory or at the
holder&#8217;s option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under one or more documents called
indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to read the applicable
prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt securities. Forms of
indentures have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants.</I></B> We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series.
We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features of the
warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant
agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration
statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement or will be incorporated by reference from reports that we file with the SEC.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be issued under an applicable warrant
agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the
heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2024, which is on file with the SEC and is incorporated herein by reference, as updated by any subsequently filed periodic reports and other documents that are incorporated by reference into this prospectus, before deciding whether
to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors described in the documents referenced above could adversely affect our business, operating results
and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we
currently believe are immaterial may also significantly impair our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related free
writing prospectus constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section&nbsp;27A of the Securities Act of
1933, as amended (the &#8220;Securities Act&#8221;), and Section&nbsp;21E of the Exchange Act. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221;
&#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions intended to identify statements about the future. From time to time, we publish forward-looking statements relating to matters such as
anticipated financial performance, business prospects, technological developments, new products, research and development activities and other aspects of our present and future business operations as well as similar matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our or our industry&#8217;s actual
results, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Although we believe that we have a reasonable basis for
each forward-looking statement contained in this prospectus, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. While it is
impossible to identify or predict all such matters, these differences may result from, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, progress and results of our preclinical studies and clinical trials of our product candidates,
including statements regarding the timing and pace of initiation, enrollment and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and plans with respect to our
research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success of our <FONT STYLE="white-space:nowrap">in-house</FONT> or third-party clinical
manufacturing capabilities and efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any submission of filings for regulatory approval of, and our ability to obtain and maintain
regulatory approvals for, our product candidates for any indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify patients with the diseases treated by our product candidates, and to enroll patients in
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the market acceptance and opportunity for and clinical utility of our product
candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the scope of any approved indication for any product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements, our need for or ability to
obtain additional funding and our ability to continue as a going concern; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations or strategic relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel, including executive officers and members of
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance upon intellectual property licensed from third parties and our ability to obtain such licenses on
commercially reasonable terms or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect and enforce our intellectual property position for our product candidates, and the scope
of such protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period over which we estimate our existing cash, cash equivalents and marketable securities will be
sufficient to fund our future operating expenses and capital expenditure requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position and the development of and projections relating to our competitors or our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of laws and regulations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating such forward-looking statements, you should specifically consider various factors, including the risks
outlined under the heading &#8220;Risk Factors&#8221; contained in this prospectus, any accompanying prospectus supplement and any related free writing prospectus, and in our most recent Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> and any Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> we subsequently file with the SEC. The discussion of
risks and uncertainties set forth in those filings is not necessarily a complete or exhaustive list of all risks facing us at any particular point in time. As a result of these factors, we cannot assure you that the forward-looking statements in
this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard
these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as
a result of new information, future events or otherwise, except as required by law. Forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based on information available to us as of the date of this prospectus. While we believe such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be
read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some
of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus, the events
and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should refer to the section titled &#8220;Risk
Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should carefully read this prospectus, any accompanying prospectus supplement and any related free writing prospectus, together with the
information incorporated herein or therein by reference, and with the understanding that our actual future results may materially differ from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any
applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby for
working capital, capital expenditures and general corporate purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans,
commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any
securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these uses, we intend to invest the net proceeds in investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our Restated Certificate authorizes us to issue up to 400,000,000 shares of common stock, $0.0001 par value
per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. As of December&nbsp;31, 2024, 124,776,152 shares of common stock were outstanding and no shares of preferred stock were outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary description of our capital stock is based on the provisions of our Restated Certificate as well as our Amended and
Restated Bylaws (&#8220;Bylaws&#8221;), and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;). This information is qualified entirely by reference to the applicable provisions of our Restated Certificate,
Bylaws and the DGCL. For information on how to obtain copies of our Restated Certificate and Bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#8220;Where You Can Find Additional Information.&#8221;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the
election of directors. The affirmative vote of holders of at least 662/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our Restated Certificate,
including provisions relating to amending our Bylaws, the classified board, the size of our board, removal of directors, director liability, vacancies on our board, special meetings, stockholder notices, actions by written consent and exclusive
forum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by our board of directors out of legally available
funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the
satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences and
Privileges </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking
fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the right of the holders of shares of any series of preferred stock that we may
designate in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights under our Investors&#8217; Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and some of the holders of our common stock have entered into an amended and restated investors&#8217; rights agreement. The registration
rights provisions of this agreement provide those holders with demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights with respect to the shares of common stock currently held by them and issuable to them upon
conversion of our preferred stock in connection with our initial public offering. The shares with registration rights are collectively referred to herein as registrable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority of registrable securities then outstanding have the right to demand that we file a registration statement covering at
least 40% of the registrable securities then outstanding (or a lesser percent if the aggregate offering price exceeds $15.0&nbsp;million net of certain selling expenses). We are obligated to effect at most two registrations in response to these
demand registration rights. These demand registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any, to limit the number of shares included in any such registration under specified
circumstances. Upon such a request, we are required to effect the registration as soon as practicable, but in any event no later than 60 days after the receipt of such request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
propose to register any of our securities under the Securities Act either for our own account or for the account of other stockholders, the holders of registrable securities will each be entitled to notice of the registration and will be entitled to
include their shares of common stock in the registration statement. These piggyback registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such
registration under specified circumstances, and do not apply to a registration relating to any equity incentive plan, stock purchase or similar plan, a transaction under Rule 145 of the Securities Act, a registration on any form that does not
include substantially the same information as would be required to be included in a registration statement covering the sale of the registrable securities or a registration related to common stock issued upon conversion of debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of at least 15% of the registrable securities then outstanding are entitled to request to have such shares registered by us on a
Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement. These Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights are subject to other specified conditions and limitations, including the condition that the
anticipated aggregate offering price, net of certain selling expenses, is at least $5.0&nbsp;million. Upon receipt of this request, the holders of registrable securities will each be entitled to participate in this registration. We will not be
required to effect such a registration if, within any twelve month period, we have already effected two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses of Registration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required
to pay all expenses, including fees and expenses of one counsel to represent the selling stockholders, relating to any demand, piggyback or Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration, other than underwriting discounts and
commissions, stock transfer taxes and any additional fees of counsel for the selling stockholders, subject to specified conditions and limitations. We are not required to pay registration expenses if a demand registration request is withdrawn at the
request of a majority of holders of registrable securities to be registered, unless holders of a majority of the registrable securities agree to forfeit their right to one demand registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amended and restated investors&#8217; rights agreement contains customary cross-indemnification provisions, pursuant to which we are
obligated to indemnify the selling stockholders in the event of material misstatements or omissions in the applicable registration statement attributable to us, and the selling stockholders are obligated to indemnify us for material misstatements or
omissions in the registration statement attributable to them, subject to certain limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights granted under the investors&#8217; rights agreement will terminate with respect to any particular stockholder upon the
earlier of (i)&nbsp;the closing of a deemed liquidation event, as defined in our Restated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Certificate; (ii)&nbsp;with respect to each stockholder, at such time such stockholder is able to sell all of its shares pursuant to Rule 144 or another similar exemption under the Securities Act
during a three-month period without registration; and (iii)&nbsp;February&nbsp;5, 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Restated Certificate, our board of directors have the authority without further action by our stockholders, to issue up to
10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any
qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of our common stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific
issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of us
and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders
of common stock until the board of directors determines the specific rights attached to that preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will
fix the designations, voting powers, preferences and rights of each series, as well as the qualifications, limitations or restrictions thereof, of the preferred stock of each series that we offer under this prospectus and applicable prospectus
supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of
any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares we are offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate per share, dividend period and payment dates and method of calculation for dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock or other securities of ours, including
depositary shares and warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period,
the exchange price, or how it will be calculated, and under what circumstances it may be adjusted; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemption rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special United States federal income tax considerations applicable to the
preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the
series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vor is incorporated in Delaware. The DGCL provides that the holders of preferred stock will have the right to vote
separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of
the class or change the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights that may be provided for in the applicable
certificate of designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antitakeover Effects of Provisions of Charter Documents and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the DGCL </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested
stockholder, with the following exceptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the
interested stockholder, those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#8220;business combination&#8221; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation or any direct or indirect majority-owned subsidiary of the
corporation and the interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder (in one transaction or a series of transactions); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation or by
any direct or indirect majority-owned subsidiary of the corporation of any stock of the corporation or of such subsidiary to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation or any direct or indirect majority-owned subsidiary of the corporation
that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#8220;interested
stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the
outstanding voting stock of the corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restated Certificate and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate provides for our board of directors to be divided into three classes with staggered three-year terms. Only one class
of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, stockholders holding a
majority of the shares of common stock outstanding will be able to elect all of our directors. Our Restated Certificate and our Bylaws also provide that directors may be removed by the stockholders only for cause upon the vote of 66<SUP
STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% or more of our outstanding common stock. Furthermore, the authorized number of directors may be changed only by resolution approved by a majority of the board of
directors, and vacancies and newly created directorships on the board of directors may, except as otherwise required by law or determined by the board, only be filled by a majority vote of the directors then serving on the board, even though less
than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Restated Certificate and Bylaws our stockholders do not have cumulative voting rights. Because of this, the
holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate and Bylaws also provide that all stockholder actions must be effected at a duly called meeting of stockholders and
will eliminate the right of stockholders to act by written consent without a meeting. Our Bylaws also provide that only the chair of our board, Chief Executive Officer or the board of directors pursuant to a resolution adopted by a majority of the
total number of authorized directors may call a special meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Bylaws provides that stockholders seeking to present
proposals before a meeting of stockholders to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and will specify requirements as to the form and content of a stockholder&#8217;s
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate and Bylaws provide that the stockholders cannot amend many of the provisions described above except by a
vote of 662&acirc;&#710;&#8226;3% or more of our outstanding common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in &#8220;&#8212;Preferred Stock&#8221; above,
our Restated Certificate gives our board of directors the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, with any rights, preferences and privileges as they may
designate, including the right to approve an acquisition or other change in control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combination of these provisions will make it more difficult for our existing
stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also
make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or
other rights or preferences that could impede the success of any attempt to change our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance
the likelihood of continued stability in the composition of our board of directors and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile
takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control
or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased
protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover
proposals could result in an improvement of their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate provides that the Court of Chancery of the state of Delaware will be the exclusive forum for the following types of
actions or proceedings under Delaware statutory or common law: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us arising pursuant to the DGCL, our Restated Certificate, or our Bylaws; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any action asserting a claim against us that is governed by the internal affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&nbsp;22 of the
Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple
jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our Restated Certificate also provide that unless we consent in writing to the selection of an alternative forum, the federal district
courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to
bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our Restated Certificate. This may
require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for
disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our Restated Certificate to be
inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Restated Certificate further provides that the federal district courts of the United
States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such
exclusive forum provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent&#8217;s address is 150 Royall
Street, Canton, Massachusetts 02021.The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on Nasdaq </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on The Nasdaq Global Select Market under the trading symbol &#8220;VOR&#8221;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act We have filed the form of indenture as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue
discount&#8221; (&#8220;OID&#8221;), for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued
with OID will be described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and
the terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or
exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of
debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain
any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a
subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the
Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following
are events of default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the
last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the
unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each
issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90&nbsp;days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if
any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified
covenants in the indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#8220;Description of Debt Securities&#8212;Consolidation,
Merger or Sale;&#8221; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#8220;Description of Debt Securities&#8212;General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the
rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be
deposited with, or on behalf of, The Depository Trust Company (&#8220;DTC&#8221;), or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series
are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of
the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any
registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will name in the
applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the
designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15&nbsp;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and
liabilities that it might incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplement and in any related
free writing prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or
more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have
summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any
applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this
prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed
forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration
statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series
of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant
certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as
well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the
applicable prospectus supplement the terms of the series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price or prices and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to force the exercise of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set
forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate, properly completed and duly executed at the corporate trust office of the
warrant agent, or any other office, indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised,
then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the
laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any
other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we
discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of
themselves or their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security.
Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to
the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have
made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors
in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an
interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a
global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be
registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other
financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they
receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not
legal holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders
of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or
has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of
the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the holders, and
not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special
Considerations for Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry
form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#8217; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor
depositary, unless special termination situations arise. We describe those situations below under &#8220;&#8212;Special Situations When A Global Security Will Be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee,
will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account
with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the
security, but only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular
security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities
through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations For Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only as global securities, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in the global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#8217;s interest in the global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its
records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an
investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When A Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, a global security will terminate when the following special situations
occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a
global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule
415(a)(4) under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price on or through the facilities of The Nasdaq Global Select Market or any other securities
exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Such at the market
offerings, if any, may be conducted by underwriters acting as principal or agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related
free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement, other than securities covered by any overallotment or other option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change
from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of
securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional
investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide
agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these
liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making
at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in
overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying
security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to
be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters or
agents who are qualified market makers on The Nasdaq Global Select Market may engage in passive market making transactions in the securities on The Nasdaq Global Select Market in accordance with Rule 103 of Regulation M under the Exchange Act,
during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market
makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market
maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be
discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of
the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, GC&amp;H Investments, LLC and GC&amp;H Investments, a California partnership,
which are entities beneficially owned by current and former partners and associates of Cooley LLP, beneficially hold an aggregate of 35,350 shares of our common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2024, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about
the Company&#8217;s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements
are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#8217;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth
in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and
schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference in this prospectus. We have not authorized anyone else to provide you with different
information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this
prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file
annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including
Vor. The address of the SEC website is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a website at www.vorbio.com. Information contained in or accessible
through our website does not constitute a part of this prospectus and is not incorporated by reference in this prospectus. We have included our website address as an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx89411_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-39979.</FONT> The documents
incorporated by reference into this prospectus contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents are
incorporated by reference into this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000095017025042623/vor-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;20, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525003259/d861124d8k.htm">January
<U></U>&nbsp;8, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1817229/000119312525021763/d921842d8k.htm">February<U></U>&nbsp;6, 2025</A> (to the extent the information in such reports is filed and
not furnished); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock as described in <A HREF="http://www.sec.gov/Archives/edgar/data/1817229/000095017025042623/vor-ex4_3.htm">Exhibit&nbsp;4.3</A> to our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> filed with the SEC on March&nbsp;20, 2025, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the initial
filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&nbsp;after the date of this prospectus but prior to the termination of the offering. These documents include
periodic reports, such as Annual Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> as well as proxy statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any
beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits
which are specifically incorporated by reference into such documents. Requests should be directed to: Vor Biopharma Inc, Attn: Investor Relations,&nbsp;100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts 02140, (617) <FONT
STYLE="white-space:nowrap">655-6580</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in this prospectus or contained in a document incorporated or deemed
to be incorporated by reference into this prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be
incorporated by reference into this prospectus, modifies or supersedes such statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>10,000,000 Shares </B></P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g89411g90j12.jpg" ALT="LOGO" STYLE="width:3.73681in;height:1.35986in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>J.P.&nbsp;Morgan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Citigroup
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>TD&nbsp;Cowen </B></P>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November 10, 2025 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g89411g51v03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g89411g51v03.jpg
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M ?(# 2(  A$! Q$!_\0 '  !  ,  P$!              8'" ,$!0(!_\0
M1Q   0," @8$!PP* P$!     0 " P0%!A$'$B$Q06$347&!%"(C,D*1H0@5
M%A=2=).QLL'1TC,U56)R@I*BPN$V4_ D0__$ !H! 0 # 0$!
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M1)[8MEHK+2+O: UH V ; B(L4TPB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M D(B( OB>6.G@DFF>V.*-I>][CD&@;22OM5-I\Q3X!:8[%2295-:-><@[6Q
M[OYB/4#UKTJK=DU% E_QAX3_ &Y2_P!WX)\8>$_VY2_W?@LH(M/]/A\LKDU?
M\8>$_P!N4O\ =^"YZ''&&Z^KBI:.[T\U1*X,9&W/-Q/ ;%DE7GH#PAT,+L1U
M\?E) 8Z-KAN;N<_OW#EGUKQNTE=4')MA/)<R(BSBP1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!5-I^I,Z6T5@'F/DB<>T C[)5LJ"Z:*3PG!$T@&9IIH
MY?;J_P"2]M.]MB)79GQ$1;)Z!$1 $1$!Z>&KS46&\TUPI3X\3O&;GL>T[VGM
M"T_:;A3W6VT]=1OUX)V![3]QYC<LFJSM"V*? :\V2LDRIJEV<!)V,D^3V.^O
MM7)JJ=\=R[15HN]$1990C=FP?;[5BFZ7RG;_ /17 >+ELC.]Y'\1R)4D1%:4
MG+E@+Q\5WIECM$M0<C.[Q(6GB[\!O7KN<&M+G$!H&9)X!4GC6^F]W=SXW'P2
M'-D(ZQQ=W_@O6BKR2YZ/*V>R/Y/"FE?-,^65Q?(]Q<YQWDG>5\(BU#@"(B$!
M$1 %<VC:GZ#"E.XC(S/?(?7E]0"IE7]AZG\$L=!!ED60,![<MOM7)JW]J1TZ
M9?<V=]$19YV!?,L;)HGQRM:^-X+7-<,P0=X*^D0&4])N%'X4Q)+3QM<:"?.6
ME>?DY[6]K3L]1XJ)+6&D?"L>*\-S4@#16Q>5IGG@\<,^H[CW'@LI3PR4\\D,
M['1RQN+'L<,BT@Y$%;FDO\L.>T4:/A>EAR[U%AO=)<Z,^5IWAV6>QPW%IY$9
MCO7FHNEI-88-FV:Y4]WM5+<*)^O3U$8D8>K/@>8W+N*C?<_8IZ.>;#M9)XDF
M<U(2=SO29WC;W'K5Y+ OJ=4W$NN0B(O$'4NUPI[5;*FOK7ZE/3QF1YY#@.?!
M9$Q->:C$%\K+G5GRE0_6#<]C&[FM'8,@K7]T#BG6?#ARCDV-RFJR#QWL9_E_
M2J56OH:=D=[[95L(B^HV.DD:R-I>]Q#6M:,R2=P"[R"2Z.L+2XKQ'#1Y.;21
M^4J9!Z+!P[3N'^EJZF@BIJ>*"G8V.&)H8QC1D&M R "BFB_";<*8;CAE:/?"
MHREJ7#Y7!O8T;.W,\5+UAZJ_RSXZ19(+YFECAB=),]L<;1FYSCD .94+TA:0
M[?A*,P- J[HX9MIVNR#.HO/ <MY]JSWBG%UYQ-.7W6L>Z+/-L#/%B9V-^\YE
M31I)V\OA!LT'>M*6%K6YS/#S62MWMI&=)_=L;[5%:K3G0-<?!;+52#@9)FL^
MH%4.B[HZ&I=\D9+SBTZTY=Y6PRM;UMJ0?\0O=M>F3#56X-JQ64)/&6+6;ZVD
MGV+-Z*7HJGTL#)LNTW>W7B#IK76T]7'Q,3P[+M'#O7>6+[=7U=MJF5-OJ9J:
M=NZ2)Y:?8KHT?:7Q-)'08KU&.=DUE<T9-)_?'#M&SEQ7'=H9068<HE,NA%^,
M<U[&N8X.:X9@@Y@A?JX20J[JM+^&J:JF@D;7Z\3RQV4(RS!R/I<E8BQI?OUY
M<?G,GVBNS241N;W>Q#>#07QS87^3</H!^9/CFPO\FX?0#\RS>B[?H:OR1DTA
M\<V%_DW#Z ?F7-!IAPI(<GS5D7-].3]1*S2B?05?D9-:VG'.&;JX-H[S2%YV
M!DCNB<3R#LLU) 00"#F"L3*4X1QW?,,2L%'5.FI ?&I9B71D<OD]R\;/3^,P
M8R:P11O V,+?BZVFHHB8ZB/(3T[SXT9^\'@5)%G2BXO$NRP1$50%XN-:3P["
M5WIP,W.IGEH_> )'M 7M+\D8'L<QPS:X9$<E,7AY!D-%V+A3FCKZFF=YT,KH
MSW$C[EUUO+D]0B(@"(B +Z8]T;VO8XM>TY@@Y$'K7RB TGHXQ,W$M@9)*X>'
M4^4=0WK/!W8?KS4J69,"8CDPU?X:L%QIG^3J&#TF'CVC>/\ :TQ3S1U$$<T#
MVR12-#V.:<PX':"%D:BKQRXZ9YM8/M$71O5RAM-LGK*@^+&-C>+G< .U>"67
MA%6\<LB>DV_^"48M=,_R\XSE(]%G5W_5VJK%V;C637"NFJJEVM+*[6<?N[%U
MEK55JN.#/LGOED(B+T/,(B( B(@.Q;:?PNX4M./_ -96L]9R6A0,AD-RI+ -
M/X3BN@:1L8XR'^4$CVY*[5P:Q_<D=FF7#81$7&=(1$0!43I[PAX/4C$=!'Y&
M8AE6UH\U^X/[]QYY=:O9=:Y4-/<K?4459&)*>=AC>T\05[46NJ:DA@Q>B]S&
M>'JC#&(*FVU.;FL.M%(1^DC/FN_'F"O#6]&2DLHH=BWUD]OKJ>LI'F.H@>)(
MW#@0<PM<X0OL&),/4=SI\ATK?*,!\QXV.;Z_9DL?*T=!&*?>J^NL]7)E1W C
MH\SL9-P_J&SMR7+K*?)#<NT2F:(7D8LOD&',/UESJ<BV%GB,S\]YV-;WG)>N
ML\Z>,4^^=[99:23.DH#G+D=CYN/](V=I*S-/5Y9J/L2RM;E6SW&OJ*VL>9*B
M=YD>X\23FNLB+>2QP5"MO0/A#P^X.Q!7QYTU*[5IFN&Q\O%W8WZ^Q5WA.Q5.
M)+]2VRD&3I7>._+,1L'G./8%K:SVVFM%KIK?0LU*>G8&,'WGF=Y7%K;]D=B[
M9*1W%"=*>-&82LP%,6NNE4"VG8=NH.+R.H>T]ZFKG!C2YQ :!F2> 62,?8@D
MQ+BBMKW.)@+NCIVGT8QL;Z]_:2N'24^6?/2);/#JJB:KJ9:BJE?+/*XO>]YS
M+B>)*XD79MM#47*O@HZ*)TM3.\,C8WB2MOA(J=9>S;<*WZYL#Z&SUTT9W/;"
M[5/>=BT%@'1I:\.4\4]=%'777(%TLC<VQGJ8#]>_LW*?+.LUZ3Q!9)P9*J<"
MXGIF%\MBK]4;]2(O^K-1Z>&2"5T<\;XY&G(M>T@CM!6UEXV)<,VG$=*Z"[4<
M<IRR;*!E(SFUV\?4JP]0>?O0P8_12S2)@RJP?=1$]QFH9LW4]1EEK#BT]3A_
MM1-:4)*:W1Z(+?T)X]?254.'KO*74LIU:25Y_1N.YA_=/#J/;LOI8G:2UP+2
M01M!'!:NT8XA.)<(4=9,[6JH_(5'-[>/>"#WK,UU"B_)'W+)DJ6-+]^O+C\Y
MD^T5LM8TOWZ\N/SF3[14^G=R(9T5WK3:;A=YWPVNCGJY6-UW,A87$#/+/9VA
M=%6O[G/_ )5<OF1^VQ=]TW7!R7L0B%? C$_[!N/T#EPU6$,14L+I:BR7%D;=
MI<:=V0[=BUZBSOU"7P6P8F17%[H+#=)1345ZHHF0OJ7NBJ&M&0<[+,.RZ\@<
M^Y4ZM&JQ6P4D5/<P5B&HPQB&EN-.7:C7:LT8/Z2,^<W\.8"US3S1U%/%/"X/
MBD:'L<.((S!6*EJ[134NJ]'MDD>22(3%W,<6CV-7%ZA!84_[$Q)6B(LLL$1$
M!FC252>!XXN\8&0=+TH_G =]ZC*L;3G2=#BNGJ /%J*9N9ZW-)'U9*N5M4O=
M6F>BZ"(B]20B(@"(B *Y=">*>EB=8*V3QXP7TKG'>W>YG=O'+/J5-+GH*N:@
MK(:JED,<\+P]CAP(7E;6K([60UDULJATC7_WSN7@=._.DI21F-SW\3W;AW]:
M]NXX\@K,&P5-"\-KZMIC<P';"X>>?;L[056JX]-2TW*1PZBS^""(B[3D"(B
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MZ]_8I!@_"ELPK;A36R+QW9=+._:^4]9/5RW!>\LC4:MV?;'A%D@B(N(D(B(
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*B( B(@"(B __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g89411g65s86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g89411g65s86.jpg
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ME3O]$5/K5UPJ,O(C;'G_ %+G_B59IU24\4;O"30 9;1
M
M                                   03IXI>2Q125")X,]*B+Q<USD^
MQ4(U)HT_TNM06BK1/(E?$J_U(BI]U2%S>X=NK#"4  /2        !F6BX5%J
MN5-74;M6>!Z/:O3P7@NXPP<F-QJ1;##UVI[Y9Z6XTB^+F9GJY[6KSM7BB[#8
M$%Z%<3=[[JZSU;\J6L=G$JKL;+T?W)LZT0G0P.1A]*\U]D0 %      (DT_8
M9[LM<-^I69STGBY\DVNC5=B]BKZ'<"!"Z%930UE)/2U+$D@F8L;VKN<U4R5"
MH^+[%-AS$5;;)\U2%_BWKY[%VM=Z/7F:O!R]5>B?9"T>[3@ T$
M ?=/#)43QPP,5\LCD8QJ;W*JY(B%M<"X?CPSAFCMS$196MUYG)YTB^4OL3@B
M$,Z!<,]\;Y)>:EF=-0;(LTV.E5-GS4V]:H6$,KG9=SZ<>RRL>X #/2
MYO'=\[SV9R0NRJZC..++>WI=V?:J'12/;'&Y\CD:QJ*YSEW(B<Y!V++RZ]WB
M6HS5(&^!"U>9J?CO[2_!CZ[=_$*<U^BO;RTY^ &D\           !*NB:GU+
M)53JFV6?+L1$_%2*B:]'\'<^$Z%%3:]'2+VN7+U9'GY4ZII?QXW=T( ,Y[@
M
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M5THZ?+/E9F,]*Y%@3Q\N?$/7QH\R  \3U
M
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MED7L:JIZ\B;"*=$]/RE]J9E39% J=JJGL125C/Y4[OI[N/&J  /,O
M
M                                             "ONFRE[GQL^7+94
M01R>C-O^)8(AOW0%+E4V>K1/*9)$Y>I45/O*>S@VUEB/N["(P ;;H
M      $OZ#L39.DL%6_8N<M*JKS[W,]J=I$![T-5-0UD-52O6.>%Z/8Y.947
M,JS8HRTFLBW(-/A*^0XAL--<(,D5[<I&)YCT\I/]\V1N#YZU9K.I1  <   "
M--.F&>^V'$NE,S.KMV;G9)M=$OE)V;_226?,C&R1NCD:CF.16N:J9HJ+S$\=
MYQVBT.3&U*P=)I#PX[#&*:NA1%[F5>5IW+SQNSR]&U.PYL^@K:+1%H5@ ).!
MD6ZBGN-?3T=(Q7U$\B1L:G.JKD8Y,/N?L,\O65&(*IGBX,X:;/G>J>$[L1<N
MU>@JS9(QTFTNQ&TPX7LT&'[#1VRFR5D#$179>6[>YW:N:FT ,"9F9W*T !P
M   .3TBWSO9:5I8'9554BM3+>UG.OL_\$J5F\ZA&UHK&Y<)CR^=^+PYL+LZ2
MGSCCRW.7G=V_8B'- &K6L5C4,ZUIM.Y  21             $F:(H,J2XU&7
ME/;&B]2*O^2$@'*Z,H.1PK$_+;-(^3UZO^)U1EYIW>6CBC5(  5+
M
M                                             CC3K2\MA.GG1-L%
M4U57@K7)]N1(YRVD^E[KP)=V(F:LC25/[7([[$4NX]NG)6?W(5H !]"D
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MON>F  'J>8              #T@C6:>.)OE/<C4ZU7(.ITPK3]S8<ML662I
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MI^453G+3YKND1/";VHF?]O$\_)XE*TZJ1X=K;[IX !F)@
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M55+:X1L4&&\/TELILE2)N;WY>6]?*=VKZLCR<K%BQ5U6.\NUF9;@ &>F
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MLTY9KEZF^%[#4'6Z,*?EL4-DR_4PO?\ 8W_(ADG5)E.D;M$)? !DM(
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M !3M)H/"@I(*"B@I*2-(Z>!B1QL3F:B9(>Y@YLLY;S:5L1H !4Z
M                                                    *X:7*7N7
M'EQR3)LR,E3M8F?K13CB3]/=+R>(+?5(FR:FU.M6N7\R$8'T'&MU8JS^R4
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M-%ZU55^Q"/"6=%,')X?FE5-LLZ^A$1/MS*.1.L<KL$;N[, &:]X
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M '*J^TA%$S7)"P=N@[EM]- FSDHFL]"9'DY<_3$/3QH[S+( !X7L
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M%5BW[FHYJM<F;53)4*D7"G6CKZFF=Y4,KHU[%5/8:GPZW:U788X --T
M              L+HBQ-W\L"4=2_.NH41CLUVO9YKO8O5Q*]&[P=?I<.7^FN
M$6:L:NK*Q//C7>GM3BB'GY.'U::]_86E!Y4E3%64L-33/22&5B/8Y-RHJ9HI
MZF B         &KQ+=H[+:)JM^2O1-6-J^<]=R>WL.Q$S.H<F=1N7$:4;YRD
MS+33N\"/)\ZISNYF]F_T=!'QZ3S23SR33.5\DCE<YR[U5=ZGF:N.D4KTPSKV
MZYV  F@                  #.L5/W5>J"#+-))V-7JUMI/Q"^CNGY?%='F
MF:1HZ1>QJY>M4)H/!RY^J(>WC1],R  \KT             #G\=8<BQ1ANJM
M\FJDRIKP2+YDB;EZN9>"J5.JZ>6DJIJ>I8Z.>%ZQO8[>UR+DJ%T2"]/F%.0J
M8\144?BIE2*J1$W/\U_:FQ>*)TGOX.;IGTY]T;1[H= !K*P    !]P2R4\\<
MT+U9+&Y'L<W>U47-%0MK@7$$>)L,T=Q;DDKFZDS4\V1-CD]J<%0J.2=H(Q+W
MKQ"ZTU+\J2X9(S-=C94\GTILZ\CQ\S%UTW'F$JSI8@ &,L    /Q[FL:KGJC
M6M3-57<B 1]IKQ-WCPLZCIWZM;<<XFY;VQ^>[T+EV\"M9U&DC$CL3XJJJQCE
M6DC7D:9.B-%7)>U<U[3ES=XV+TJ:GS*N9V  ]"(     V&'[34WR\TEMHFYS
M5#T:B\S4YW+P1,U["V]AM5-9+12VZB;JP4[$8G2J\ZKQ5<U[2-M V%.X+6^_
M5D>536-U8$5-K8L]_P#<OJ1.DE@Q^9FZ[=,>(65C0 #Q)!XUM5!0TDU55RMA
MIX6J][W+DC43G/8KUIHQPMYKWV6V2_\ TVF?E*]J[)I$_P 4]:[>@NP89S6Z
M8<F=-+I,QW4XLKUAIU?#:(7>*ASR5Z_MNX]"<WI.( -RE(I'356  FX
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MEDCIUE3^]$=[2S9 6G*EY#&+)D3944S'JO%%<W[$0]WP^VLDQ]X=A'@ -ET
M                    3-H/Q-RD,E@JW^''G)2JJ[V^<SLWIUKT$M%2;973
MVVX4];2/U)X'H]B\4]A:/#5X@OUDI;C3+X,S?";GM8Y-BM7J4Q^=AZ+=<>)<
MELP >!P     "'=(5\[ZW=8('YTE*JL;EN<[G=[.SB=WC^^=Z+.Z.%V574YL
MCRWM3G=_OG4AH]G%Q_GEY>1?\L  /:\@                     [K1+3Z]
MWK)U39'#J]KG)^524C@]$<&K;:^HR_62HSYJ9_Y'>&9R)WDEH8(U2  %*T
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MHKG.5<D1$YRI^D/$;L3XIJZY'+W,B\E3M7FC;N].U>T]?#Q>I?<^(1M.H<V
M#:5@     =/HYPP_%.)H*-4<E)'XVI>G-&B[NM=W;P.81%541$S52T.B;"J8
M9PRSNAF5QK,IJC/>W]EG8GK53S<G-Z5.WF4JQMV<,;(8F11,:R-C4:UK4R1$
M3<B'T 8:P /Q[FL8Y[W(UK4S55W(@' :9<6KAW#W<E')JW&N18V*B[8V><_V
M)Q7@5I.CT@XA?B;%-97ZRK3H[DJ=%YHVYY>G?UJ<X;O&P^E37O*N9V  ]"(
M  /2F@EJJB."FC?+-(Y&L8Q,U<J[D1"=]'VB2FHHXZ[%#&U-6N3FTF><<?\
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MO0KSI%T=UN%)%JH%=5VERY-F1/"CSW(]/;N7AN-#!RZY?IGM*$UTX4 'K1
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MWJ\352YI%Y$35\UB;OQ[34 &K$16-0S9G<[D !UP
M 3-HWI^0PI3.5,EE<^1?G*GV(ATQK\.4_<MAM\.62M@9GUY;?6; R+SNTRTZ
M1JL0  BD                _'M:]CF/:CFN3)45,T5"J^D["SL+8FF@B:O<
M,^<U,[XJKM;UHNSJRZ2U)R&E#"S<4X9FAB:BU]/G-3.YU<F]O4Y-G7ET'IXN
M;TK]_$N3&X58!^N:YCE:]%:YJY*B[T4_#<5     #]C>Z-[7QN5KVJBHY%R5
M%3G+8:.L1MQ/A:DKE5.Z6IR50U.:1N_T[%[2IQ(NA#$W>7$Z4%0_*CN.42YK
ML;+YB]N:IVIT'DY>+U*;CS"59TLB ?,TC(8GRRN1D;&JYSE7)$1-ZF*L1MIS
MQ-WHPVELIGY5EQS:[)=K8D\I>W=Z>@KH=#CW$+\38GK+@JKR"KR<#5\V--WI
MWKQ53GC=XV+TJ1'NJF=@ /0X    9%NHY[C74]'21K)43O2-C4YU5<CG@2!H
M2PIW[Q!WRJX\Z"WN1VU-CY=[4[-Z]G26.--@ZP08:P]2VVGR58VYR/1/UCU\
MIWI]61N3"Y&;U;[]EL1J  %#H<+IFO:V;!%4R)VK45JI2LRWHBYZR_-14[4.
MZ*_^Z&NJU&(Z&VL=FRD@UW)\=Z_@C?2>CBTZ\L0Y,ZA%( -U4    2#H5PPV
M_8H[JJF:U%;T25Z*FQS\_ ;Z45>SB0R7BE9M/L[$;23H>P&RQ4#+M=(D6[5#
M<V-<G_IV+S?U+S^CISDP P,F2<ENJRV(T  @      >=3!%54\D%3&R6&1JM
M>QZ9HY%WHJ'H *PZ5,%/PG=TDI4<ZU52JL#EVZB\[%7AS=*=2G#EO,8V&#$F
M'JNVU"(BR-SB>J>1(GDN]/JS*D5E-+1U<U-4L5DT+UC>U>9R+DJ>HVN)G]6N
MI\PKM&GD #UH@  W>";T[#^*+?<4549%*B2HG/&NQR>A5+=-<CVHYJHK53-%
M3G0I46JT5W5;O@2U3/=K2Q1]SR=.;%U=O6B(O:9O/IVB_P#"=)]G6  S$VNQ
M)\';K\DE^XXIT7%Q)\';K\DE^XXIT:GP_P 60L  T4   2=[GKX;57R!_P!^
M,L05W]SU\-JKY _[\98@QN;^*LKX  >-(   KM[H&A938R@J8T1.ZJ5KG\7-
M56_8C2Q)7GW0E8R?&%+3,5%6GI&H_@YSG+EZ-7TGLX._5[(V\(O !LJP  "P
MON=Y%=@ZNC7S*YV74K&%>BPGN=XU;@^ND7SJYR)V1L/'S?PDJ^4I  QE@  !
MSFD>E[LP/>8LLU2!9$_L5'?XG1GA7TZ5=#4TSO)FC=&O:BI[25+=-HG["HP/
MI[58]S')DYJY*A\GTJ0                       #J='&)%PWB**:1R]Q3
M^*J$^*NYW8NWJSZ2RS7(]J.8J.:J9HJ;E0J 3SH7Q-WSL[K35/SJZ)J<FJKM
M?%S>C=U9&;S\.X]2/Y<E(X ,IQB7>X0VNW3UE0OBXFYY?M+S(G6I ]QK);A7
M3U=0[6EE<KEX<.I#K])U\[KKFVVG=G!3KG(J>=)T=GVJIPYH<;'TUZI\R\6>
M_5.H]@ 'I><                     #VHH5J*R"!-\DC6)VKD>)N\%4_=.
M*;:S+-$EU_FHKO8<M.HF4JQN8A.#41K4:FQ$3)#] ,=I@
M     "O&G/"G>F]I>*./*BKW+RB(FQDV]?G;^O,C N#BFR4^(;%5VRK3P)F9
M-=EM8Y/)<G4N14F[6^HM5RJ:"M9J5%.]8WIQ3G3ASFQP\WJ4Z9\PKM&F( #V
MH@  'ZURL<CFJJ.1<T5-Z*?@ M=HUQ(F)\*TU6]R+5Q^)J4_]Q$W]J9+VG,:
M=\3=Z\/LM%,_*JN&:/R7:V%-_I79U9D;:&\5LPYB-T-;*D=NK6ZDKG+L8Y/)
M=]J=O Y['%_DQ+B6LN3\TC>[5A8OFQIL:GM7BJF;3BZS[]H[I]79H@ :2
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MFJGQ5<JIZE0TQV^F.E[FQW6/1,DGCCE3YNJOK:IQ!]'AMU4B?V2  6
M                &SPU>)[#>J6XTJ^'"[-S<]CV\[5ZT-8#DQ$QJ1;>UUT%
MSMU/6TC]>"=B/8O!?::W%]Z;9+-+.U4[H?X$+5YW+S]F\C30AB?D9I+#6291
MR9RTRN7<[>YO;O\ 3TGGCB]]^;R]8G9TD&<<70O2[M^S(Q?EIKEFL^(49K]%
M7/O<Y[W/>JN<Y<U5=ZJ?(![6>                        '8Z+(.5Q(^5
M4V0P.=VJJ)[5..)'T0T^RY5"I^Q&B^E5]A5GG6.5N&-WA(H ,MH
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M9_YD5DY:>J7E,.T%4B9K#4ZG4CFK[6H0:;O"MO#"4  /4
M        ?CE1K55=R ?$M2^F5KX7JV5%S:Y-Z<3KK76-KJ-DS<D=N<G0IP,K
MUD>KE[#98>N'<59JR+E#+X+N"\RE62O5#RYHZXV[8 'F>(
M          )=T6P<EAI9%3;-.YV?!,F^Q2(B<\%T_<V%[:S+)5B1_P [PO:>
M;E3JFGHX\?5MN0 9[V@                       (_TS84_2##BU=+'K7&
M@19&9)M>SSF^U.*<2M)=8K+IAPI^CF)'3TL>K;JY5EBR38QWG,[%7-."\#2X
M.;_'/\(6CW<& #30          !]0Q/FE9%$QSY'N1K6M3-55=B(A:W1SAAF
M%L,P4:HU:N3QM2].>1>;J3=V<2*- V%.[[F^_5D>=-1NU:=%38^7I_M3UJG0
M3\97.S;GTX]DZQ[@ ,],     ?CD1S5:NU%3)2F%; M+65%.[RHI',7L54]A
M= J?I,H5MV.[U!EDCJA96]3_  T^\:'P^WU6A"SF0 :J   /UCE8]KFKDYJY
MHI<NTU;;A:Z.LC5%940LE3+H<B+[2F99;0?>4N>"(:=SLYZ!ZT[DY]7>U>K)
M<NPS^?3=(M]DZ)  !E)@          $2>Z+KDCL%KH47PIJE9<N#&JGVO0EL
MK9ISO*7/&CZ:)VM#01I!LW:^]WVHG]IZN'3JRQ/V1MX1X #;5@  $L>YTIU?
MB2Z5/-'2)'\YZ+_B1.3U[G.@6*QW6N5,N7G;$B\&-S_S/-R[:Q2E7REP &&L
M:[$GP=NOR27[CBG1<7$GP=NOR27[CBG1J?#_ !9"P #10
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M*;DCR@JGT=5'-'O:NU.E.=#OZ>9E1 R6)<V/3-#SY*ZG;RY:=,[AZ  K5
M                  #Z8U7N1K4S55R1"PM)"E/2PPMW1L:Q.Q,B,L$X-FJI
M(:^Y(Z&G:J/CCW.DRVHJ]"?:2D>#DWBTQ$>SV\>DQ$S( #RO0
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MC<W\N3_UV)06#UJ:>:EJ)(*F)\4T:ZKV/3)6KT*AY&HZ
M &/62ZK-1-Z[^H.3.H8U3+RDFSR4V(>0!%3Y  ' Z#"MPY.5:25? >N;%7F7
MH[3GS]:Y6N1S55'(N:*G,1M&XTY:O5&DD@P;-7)7T39%RY1O@O3B9QYIC79X
MIC4ZD !QP              #-M-LJKK6-IJ&)9)%W]#4Z57F03.N\NQ&_#%A
MBDGE9%"QSY'KDUK4S55)/P=@B.BU*R[M;)4[V0[VQ]?2OJ-SA3"U+8HD>N4U
M:Y/"F5-W!O0GVG0G@S<CJ^FOA[,6#7>P #RO0
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M RY)R7FTK8C0 "MUKL2?!VZ_))?N.*=%Q<2?!VZ_))?N.*=&I\/\60L  T4
M  2=[GKX;57R!_WXRQ!7?W/7PVJOD#_OQEB#&YOXJRO@ !XTE>=.6$N]-X2\
MT4>5%7.7E$1-D<V]>QV_KS(O+BXCL]-?K+5VVM;G#.S5SRVM7F<G%%R4J3?K
M54V2[U5NKFZL].]6+T.3F<G!4R7M-CAYNNO3/F%=HTP  >U$  $F:$<7=Y;T
MMIK9,K?7N1&JJ[(Y=R+U+N7L+%%*47)<TV*6;T0XN_2;#R0U<F=SHD2.;-=L
MC?-?VY9+Q3B9G.P?Y(_E.L^SNP 9J8             Y/'."*#%%.KU1*>XL
M3*.H:F_@Y.=/6A7V_P!DK[#<'T=S@6*5-K5WM>G2U>="UQJ\1V&@Q#;W4ESA
M1[-['IL?&O2U>93V<;ESB^FW>'8E5,'4XWP77X6J<Y46>@>N452U-B\'="_[
M0Y8V:7B\=59[.@ )           /Q[D8Q7.W(:M[E>]7+O4R*R76=J)N3?UF
M,1E5>=R  (     #86.O6@K4<Y?%/\%Z<.GL.Z145$5%S1=RD:G686N'+0+2
MRKXR-/ XM_[%.2ONIRT_-#?  I>8            [/!^"YKGJ5=R1T-%O:W<
MZ7\$X_\ DC>\4C<I5K-IU#488PW5WZ?Q2<E2M7QD[DV)P3I4F"R6BDLU&E/1
M1ZJ;W/7:YZ]*J9=+3PTM.R"FC;%$Q,FL:F2(AZF=ES3D_P!/=CQ13_8 "E:
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MS3BMU0Y,;4M!W^E'1_/A:K=64+7RV:5W@OWK"J^8[AT+[3@#<I>N2O557K0
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MLO3$?-O93KM1O%W2O [[=N ,Z]YO.Y>ZE(I&H  02
M                   KMIQPIWGOJ7:DCRH:]RJ]$38R;>J=N_TEB34XKL=/
MB.PU=LJLD;,WP'Y;6/3R7)U*7\?+Z5]^SDQN%/P95TH*BV7&IH:QBQU%.]8W
MMXI[#.PC89\27^DME-FBRNSD?EY#$\IW8GKR-R;1$=7LK2AH!PIK/DQ'6Q[&
MYQ4B.3GW.?\ XIVDW&-;*&"VV^GHJ.-(Z>!B1L:G,B&28.;+.6\VE9$:  5.
M@               /*KIH:NFEIZJ)DT$K5:^-Z9HY%YE0@#23HMJ+.Z6XX?8
M^IMOE/@3PI(/S-X[TY^DL("[#GMAG=7)C:E(+(XZT66S$"R5=L5MON3MJJUO
MBI%^,U-R\4]"D$XFPM=\-U"QW:C?&Q5R;,WPHW]3MW9O-?#R*9?'E7,::0 '
MH<            :BN5$:BJJ[$1.<D7!>BF\7Q8ZBYHZV4"[<Y&^->GQ6\W6O
MK(7R5QQNTNQ&W#V:U5MYKXZ*V4[ZBID78UB;N*KS)Q4L5HVT<TF%HVUE<K*J
M\.3]9EX,/!G'XWV'387PU:\,T/<UIIFQHOER+M?(O2YW/]AN3)Y'+G)]->T)
MQ70 #QI     #78D^#MU^22_<<4Z+BXD^#MU^22_<<4Z-3X?XLA8 !HH   D
M[W/7PVJOD#_OQEB"N_N>OAM5?('_ 'XRQ!C<W\597P  \:0  .8TBX7CQ5AN
M>CR:E7'XVF>OFO3FZEW+UY\Q5.>&2GGDAG8Z.6-RL>QR9*U47)44NF03IZPE
MW-5MQ%0QY0SJC*I&IY+^9_;N7CETFAP<W3/IS[HVCW0^ #55@  ]*:>6FJ(I
MZ=[HYHG(]CVKDK7(N:*A:W1YB>+%>'(:U%:VJ9XNIC3S9$WKU+O3KX%3CL-%
MV+'85Q&R29R][ZG**I;T)S/ZVKZLSR\K#ZM.WF$JSI:8'XQ[9&->QR.8Y,T<
MBYHJ=(,18_0               #CL>8$HL3PNGCU::YM3P)T38_@].=..]/4
M=B"5+VI/56>XJ?>[16V2X24=R@=#.SIW.3I1>=#7EJ,3X<M^)+>M+<8L\ML<
MK=CXUZ47V;BO>,\(7#"U7JU+>5I'KE%4L3P7<%Z%X?:;7'Y5<O:>TI1+FP >
ML #YE>D;%<O,!CULN2<FW>N\PS]<Y7.55WJ?A%1,[D  <           39N.
MXL%?W=1IKKXZ/P7\>A3AS,M-:Z@K&RIFK%V/3I0A>O5"&2O5#O@?D;VR,:]B
MHK7)FBISH?IYGD  ' W.&\/5E]J=2G;J0-7QDSD\%OXKP-K@_!L]W5E57:T%
M!O3F=+U="<26*.E@HJ9E/2Q-BA8F36M38AYLW(BO:OEZ,6&;=[>&'8;)1V2D
MY"C9M7RY'>4]>*^PV0!X)F9G<O9$1':  ''0
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M\@\]^=DM_;V=BL.9PQ@:PX;U7V^B:ZI3_P#(F\.3L5=W8B'3 'DM:;3NTI
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MAQ98L/P6VXVV&L= JMBD;5-3*/F:N?1M3JR!WP/-;)U3N8AW0 "MT
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M81$1$1$R1-R( #R/2
M
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M=39F-R.3.7M'A.*Z  >5(
M
M
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M="'T8V;/;-.Y\+(C0 "AT
M
M
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MF2V2>JRR(T  K=
M
M
M        CK29HVIL2,DK[6C*:\(F:\S)^#NA?C>GA(H)X\EL<]528VIC<**I
MMU9+25T+X*F)VJ^-Z9*BFQPKANXXGN;:*UPZSM\DCMC(F]+E_P!JI8'2WAFV
M7?#\U?4PJVMI43DYH\D<J9Y:J[-J;3IL+V"WX=M4=%:X$CC1$5SEVND=^TY>
M=32MS?\ Y]41W0Z>[7X&P;;L(V_DJ1O*U<B)RU2Y/">O0G0WA]ITP!F6M-IW
M9, !$
M
8                             ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g89411g90j12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g89411g90j12.jpg
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M=(*2E+&R%U)BHL+2,T-R@_ DD^$T4U3Q1$5C_\0 &@$!  (# 0
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M5^6(K>8J[,<S-8F0 &M,
M
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MLB_:55]IGCSVV#FMNI:?++DHFL]"9'H*:T[M,K2L:B(  19
M
M                                       "K>,Z7F6++O B9-;52*U/
MX5<JIZE0M(5XTQTO-L=5;T3))XXY4^[J_FU3LX4ZO,)5:2 "S3
M )JT)8FYS1R6.K?G-3HKZ=57QF=+>Y?4O A4]EFN,]INE-7TCM6>!Z/;U+UH
MO!4V&K-C[E9JQ,;6Q!X+#=(+U:*6X4BYQ3LULNEJ]+5XHN:'O*:8U.I:P &
M   Q&+K'#B+#U;;*C).69X#U\AZ;6N[ER,N#,3-9W I;74LU#63TM4Q8YX'K
M'(U>AR+DJ>HZ"7OA 89YI<X+]2LRAJ\HJC+HD1-B]Z)_+Q(A/08<D9:1:$
M&T        >JU4$]TN--0T;->HJ)$C8G%5R]!;W#5G@L-CH[92I\W3QHW6RR
MUG;U<O%5S7O(>^#YAGE:BIQ#5,\&+."ES3RE\=W<FSO7J)S*CG9>JW1'B$H@
M !P,@     :-I/OG-:)MLIWY35"9RJB^*SJ[_P D7K-PN5;#;J">KJ7911-5
MR\>"<5W$#7:OFN=QGK*A<Y)79Y=2=")V(=7%Q=5NJ?$-&>_3&H]WD !8N$
M         ]UCI^=7FA@RS22=C5[-;:>$V/1Y3\OBRBS3-(]:1>YJY>O(C>=5
MF4J1NT0FH %,LP
M
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MJ^HR\>5K,_\ 2F?]1IY$ZQRVX8W>&_  JE@
M
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MLD "N=@
M
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M188CK+_75=55UF4K63R*[DH_)3;N5=Z]J=1NAPWKTVFN]L@ (@
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M9)DFX %(D
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M2=G209QQ=2];N]?5D;L&/N6]?#5EOT5_]:Z]SGO<]ZJYSES55WJI\ +57@
M                EO153\EAR254VS3N=GP1$3V*;D8/!%/S;"MN9EDKH^4^
M\JN]IG"HRSN\RLL<:K$  -:8       #$8LL5/B.P5=LJLD;,WP'Y;6/3:UR
M=BE1[I05%LN-30UC%CJ*=ZQO;Q3V%SR%]/\ A37BCQ'11^$S**K1$WIN:_\
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MYTM.Y-NHY^;_ +J;?4:1=--&':95;10UM:Y-RMC1C5[W+GZC93#>_P!L&TG
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MJJD5NS>UG2O?N]/41"9'$-TDO%VGK)<T1ZY,;^ZU-R&.+;#C[==>ZNRWZ[;
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ME*P .)D     #&XG^C5V^J2_H4R1C<3_ $:NWU27]"DJ_= IP #TB
M    !RCD?$]'QO<QR;E:N2H<0!M5ET@8GM"M2FN]1)&G^74+RK<NKPL\N[(D
M?#>FZ-ZMBQ%;^3SV+/2KFG>Q=OH5>P@X&B_'QW\P;7(L=\ME]I><6BMAJHNG
M47:W@Y-Z+VF1*96JYUMIK&5=LJI::H9N?&[)>Q>M."D[:.M+-/=GQ6_$?)TM
M<[)K*A-D4J]2_NKZEX;BMS\*V/ZJ^L)1*5P <3(        5\TSTO-\<3R99
M)40QR^K5_I+!D,Z?:75K[35HGCQ/B5?]*HJ?J4ZN).LC-?**  6K8
M            2WH0Q-J226"K?X+LY:557<N]S/;Z2)#NHJF:BJX:FF>L<\+T
M>QR="HN:&O+CC)6:RQ,;6W!A\(WR'$-AIKA#DCGIJRL3R'IXR?\ .A4,P4LQ
M,3J6L !@        ".M*=\R:RT4[MJY/G5/Y6^WT&[7VYQ6BUSUDV2I&G@M_
M>=T(0/65,M952U-0Y7RRN5SEXJ=?%Q=4]4^SGSWU'3#I !8.(
M        V;1Q3\OBRE54S2)'R+]U43UJAK)OFB.GUKK75&7^'"C/O.S_ *37
MFG6.9;,4;O"40 5"Q             !=J9*5>TN84^3.)GNIF:MNK,YH,DV-
M7/PF=RKZ%0M":SI%PQ'BK#-119-2J9\[3/7R9$W)V+N7M.GBYNU?U\2Q,*F
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MPQ,NZ^7BNOEREKKI4.GJ)-ZKN:G0B)T)P,> 7$1$1J$0 &0
M  !*FB[2?-9GQ6N_R.FMBY-CF7:^G][?6G1U%@H98YX62PO;)$]J.:]JYHY%
MW*BE*24M#VD%UDJ8[/>)56URNRBD<O\ Z=RK^E>GJW]97<KB=7UT\LQ*PX"*
MBIFFU 520  !C<3_ $:NWU27]"F2,;B?Z-7;ZI+^A25?N@4X !Z1
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M=G34JY.RW.DZ?1N])II]555555557:JJ?"WI2*5BL*VUIM.Y  21
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MDJ*;,62<5XM I2#9=(6&9,+8FJ:%4<M,[YVG>OE1KN[TW+V&M'H*VBT1:$
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M*<  ](@   25\'[Z=O\ J<GYM(U)*^#]].W_ %.3\VFCD?RK?V(6/ !0)@
M'":*.>%\4S&R12-5KF.3-'(N]%0Y@"IFD;#R89Q964$:+S9526!5_P#;=N3N
M7-.XUDF'X2$#&W:RSHB:[X)&+V-<BI^I2'CT''O-\<6E"0 &X  !8;X.]4LN
M$:VG<N?(5:JG!'-:OYHI*9#7P;7*M#?6="21+Z4=[B92AY4:RV2CP  YV0
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M\&Y5"IO5D:+Z57V$BFH:+:?DL,K(J;9IG.[DR;[#;RJSSO)*QPQJD  -+8
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ML+6V/++.)'_>\+VF9.JDA2GI886[HV(Q.Y,CM*6T[F96E8U&@ &&0
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M;3U,?CPR-D;VHN9&T;K,"Z0.JCJ&5=)#40KG',QLC5ZT5,T.T\VF
M     (R^$),D>"((\]LM8QOH:]?85S)K^$A<$5UFMS5VHCZAZ>AK?R<0H7?"
MKK%",@ .M@  $G?!ZC5^-JE_0RB>O\[$+%D$_!NI=:YWJKRV1PQQ9_ZG*O\
M03L4G-G>64H\!C<3_1J[?5)?T*9(QN)_HU=OJDOZ%.:OW0RIP #TB
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M+=#EFCIV9]B+FOJ0QIM&C6#EL5T[LLTA8^1?1E[2.2=5F4Z1NT0F4 %,L@
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MQ>MJ]"E?\=8(KL,3K(FM46URY,J$3Q>#TZ%]2EI@Y,9/2WE.)VU( '4D
M               8VNFUY-1J^"WUJ>NLFY*+9XSMB&*)TCW:[S[  -C6&6PY
M<.9UG)R+E#+L7@O0IB08F-QI&8B8U*3 8?#5PYW2<E(N<T6Q>*="F8.:8U.G
M#:O3.I  81                 #/X6PQ5WZ?-B+%1M7PYE39V)UJ8M:*QN4
MHB;3J&.LUJJ[Q6-IJ&)7OWN<NQK$ZU7H)APKAFEL$"JSYVK>F4DRIOX)U(9"
MS6JDL]&VFH8D8S>YR[7/7K5>E3W%;FY$Y/2/#MQ88IZSY  <[<
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M^E.DY>5@[M/3S!$K7@X0RQSPQRPO:^*1J.:YJYHY%W*AS*-,
M #KJ((JF"2&HC9+#(FJ]CTS1R=2H=@ @_2%HUEMO*W"P,?-1>-)3IM?%Q3K;
MZTXD9%O2,](6C:*Y<K<+"QD-=XTE/N9+Q3J=ZEX;SOP<K^F_^THM^4' [*F"
M6FGD@J(WQ31KJO8],E:O4J'66"8             'Q51$55V(A]/#<)O\IJ\
M7&8C;$SJ'EJ)5ED5R[NA.!U@&UH  9   >FW5;Z*K9,S;DOA)UITH2!!*R>%
MDL:YL>F:*1L;'A.X:KEHY5V.VQJO0O2AKR5W&VC-3<;AM( -#D
M    '**-\LC8XFN>]RY-:U,U5>I"3L&X'92ZE;>6-?/O9 NUK.+NM>&XUY,M
M<<;E.E)O.H87!V"I;CJ5ET1T5'O;'N=+[D_YQ)3IX(J:!D-/&V.)B9-8U,D1
M#L!69,MLD[EWTQQ2/0 !K3                                0QI_PI
MRD,>(Z*/PX\HJM&IO;N:_NW+VIU$&ETZVEAK:.>EJHTD@F8L<C%W.:J9*A4G
M&V'IL,8CJK;-FYC%UX9%\N-?%7V+Q12VX.;JKVY\PC,,$ "P8  ![[#:JF]W
MBDMU$W6GJ'HQ.IJ=*KP1,U[BW6'[336*S4EMHFY04[$8B]+EZ7+Q5<U[R,]
M>%.96Z2_UL>515)J4R*FUL6>UWVE3T)Q)<*;FYNNW1'B$H@ !Q,@
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M&-PEA.EL4:2R93USD\*54V-X-ZNTV0 K;6FT[EW5K%8U  "+(
M                       !'>FK"GQ]AQ:ZDCUKA;T61N2;7Q^4WVIV+UDB
M GCO..T6@4F!O6E["GR:Q,]]-'JVZMSE@R38Q<_"9W*NS@J&BGH*7B]8M" ;
M+H\PS)BK$U/0HCDIF_.U+T\F--_>NQ$[36BS^B#"GR:PRV2ICU;C6Y2SYIM8
MGDL[D7;Q533R<W:IN/,D0W>GACIX(X8&-9%&U&,:U,D:B)DB(<P"B3
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M<.1HR;QI*1-C7\6=2\-W5QAN2-\4CHY6N8]JY.:Y,E1>I4+;%EKDC=4XG;B
M#8R   >:MFY./51?"=ZD/0YR-:KG+L0P\TBRR*Y>G=P)5C:%IU#@ #:U
M       &X87N'.*;F\B_.Q)LSZ6_^#3SOH:E]'51SQ^,U=W6G2A&U=PA>G5&
MDB@ZJ6=E33LFB7-CTS0[3G<( ##  ?6M5SD:U%5RKDB)O4#X;=@_!L]W5E56
MZT%!O3H=+V=2<3-8-P-JZE;>V9KXS*9>CB_W>GJ)%1$1$1$1$38B(<>;DZ^F
MCJQ8-^MG314L%%3,IZ2)L4+$R:UJ;$.X X'6
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M%!7UU/5T;G<I"D:.18W+XR;>A=_;VG%S+8LD=59]89ANH *Y(
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MF_TU\.W%ABOK;R  Y6\
M    #XYK79:S47)<TS3<O6?0                                !T5-
M%2U2955-!,G5)&COS,9+A/#TJYR6*U.7K6DCS_(S0,Q:8\2,"W!N&FKFE@M7
M?2L7V'MIK%::546FM=!"J=,=.QOY(9$&9O:?,@U$:F341$ZD !$
M                                                          /+
M=+?2W2BDI+A R>GD3)S')ZTZEXGJ B=>!7O'^C^JPZY]71:]3:E7/7RS=%P=
MPX_D1C5S<K*N7BIL0NA(QDD;F2-:]CD5KFN3-%3J5""-*.BQ]#RUVPS$Y])M
M?-2-3-T76K.MO#>G9NM.+RHF>G)Y+3,PA\ %D@                &0LE>M
M!6M>J_-/\%Z<.ON,>2UHNT7273DKKB.-T5!L=%3+L=-Q=U-]:]F_5ER5QUW9
MB:]4:9G!^$ZB^N;42JL-OW\ITR<&^\EVVT%-;:1E-11-BA;N1.GBO6IWPQ1P
MQ,BA8V.-B(UK&IDC43<B(<BDRYK9)]?!CQQ3P  TM@
M
M
M                        (CTHZ+67+EKKAN)L=;M=-2IL;-UJWJ=PW+V[
MX%EC?#*^.5CF2,56N:Y,E:J;T5"ZQ'VDO1Q2XHB?6V_4IKPU-C]S9LNA_'J=
MZ>%AQN9T_1D\,3"LX/5<Z"JM==-1W"!\%3$[5?&],E3_ ,<3REK$[]81  9
M        Y,8Z1[61M5SW+DC43-57J0[J"CJ+A614M%"^>HE=JLC8F:N4L5HQ
MT:T^&F1W"ZHRHO"IFG2RGX-ZW?Q>CCHSYZX8W/DB-L)HNT6-I.1NV)XD?4;'
MPT;MJ1]3G]:\.CIV[IB *3+EMEMU63  :P
M
M
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M*#"%'K-U:BYR-RFJ53;_ *6]3?SZ>&X %->\WGJMY2  1
M
M
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M(>6QVBAL=MBH;9 V"FC38U-ZKTJJ]*KUGO *F9F9W*0 #
M
M
M                                             NU-IHDNBW#LF)TN
MZP*D?C+1)_@K)GXV75_#N_( G2]J?;.AO;41J(C41$38B( "
M
M
0                  /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
